

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2005302155 B2**

(54) Title
Antisense antiviral compounds and methods for treating filovirus infection

(51) International Patent Classification(s)
C07H 21/04 (2006.01) **A61K 31/70** (2006.01)

(21) Application No: **2005302155** (22) Date of Filing: **2005.11.01**

(87) WIPO No: **WO06/050414**

(30) Priority Data

(31) Number	(32) Date	(33) Country
60/671,694	2005.04.14	US
60/624,277	2004.11.01	US
11/264,444	2005.10.31	US

(43) Publication Date: **2006.05.11**

(44) Accepted Journal Date: **2012.09.06**

(71) Applicant(s)
AVI BioPharma, Inc.; Government of the United States, as represented by the Secretary of the Army

(72) Inventor(s)
Stein, David A.; Iversen, Patrick L.; Bavari, Sina

(74) Agent / Attorney
Davies Collison Cave, Level 10 301 Coronation Drive, Milton, QLD, 4064

(56) Related Art
Geisbert, T.W. et al. Expert Reviews in Molecular Medicine. 2004, 6(2): 1 - 24

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 May 2006 (11.05.2006)

PCT

(10) International Publication Number
WO 2006/050414 A2

- (51) International Patent Classification: A61K 48/00 (2006.01) Sina [US/US]; 5761 Stoney Creek Drive, Frederick, MD 21703 (US).
- (21) International Application Number: PCT/US2005/039607 (74) Agents: FRESCHI, Gina, C., et al.; Perkins Coie LLP, P.O. Box 2168, Menlo Park, California 94026 (US).
- (22) International Filing Date: 1 November 2005 (01.11.2005) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, YU, ZA, ZM, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/624,277 1 November 2004 (01.11.2004) US
60/671,694 14 April 2005 (14.04.2005) US
11/264,444 31 October 2005 (31.10.2005) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 11/264,444 (CON)
Filed on 31 October 2005 (31.10.2005)
- (71) Applicant (for all designated States except US): AVI BIOPHARMA, INC. [US/US]; 4575 S.w. Research Way, #200, Corvallis, OR 97333 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): STEIN, David, A. [US/US]; 2135 N.w. Evergreen Street, Corvallis, OR 97330 (US). IVERSEN, Patrick, L. [US/US]; 5902 N.w. Fair Oaks Place, Corvallis, OR 97330 (US). BAVARI,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING FILOVIRUS INFECTION

(57) Abstract: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having: a) a nuclease resistant backbone, b) 15-40 nucleotide bases, and c) a targeting sequence of at least 15 bases in length that hybridizes to a target region selected from the following: i) the AUG start site region of VP35, as exemplified by antisense compounds SEQ ID NO: 21-26, ii) the AUG start site region of VP24, as exemplified by antisense compound SEQ ID NO:34, iii) the region 85 to 65 base pairs upstream of the AUG start site of VP24, as exemplified by SEQ ID NO:39, iv) the AUG start site region of polymerase L, as exemplified by antisense compound SEQ ID NO: 17, and v) combinations of (i), (ii), (iii), and/or (iv).

WO 2006/050414 A2

Antisense Antiviral Compounds and Methods for Treating a Filovirus Infection**Field of the Invention**

5 This invention relates to antisense oligonucleotide compounds for use in treating an infection by a virus of the Filoviridae family and antiviral treatment methods employing the compounds. More specifically, it relates to treatment methods and compounds for treating viral infections in mammals including primates by Ebola and Marburg viruses.

10 References

- Agrawal, S., et al., Proc Natl Acad Sci U S A **87**(4): 1401-5, (1990).
Arora, V. and Iversen, P.L., Curr Opin Mol Ther **3**(3): 249-57, (2001).
Blommers, M.J., et al., Nucleic Acids Res **22**(20): 4187-94, (1994).
Bonham, M.A., et al., Nucleic Acids Res **23**(7): 1197-203, (1995).
15 Borio, L., et al., Jama **287**(18): 2391-405, (2002).
Boudvillain, M., et al., Biochemistry **36**(10): 2925-31, (1997).
Bray, M., et al., J Infect Dis **178**(3): 651-61, (1998).
Burnett, J., et al., Nat Rev Drug Disc **4**: 281-297, (2005).
Connolly, B.M., et al., J Infect Dis **179** **Suppl 1**: S203-17, (1999).
20 Cross, C.W., et al., Biochemistry **36**(14): 4096-107, (1997).
Dagle, J.M., et al., Nucleic Acids Res **28**(10): 2153-7, (2000).
Ding, D., et al., Nucleic Acids Res **24**(2): 354-60, (1996).
Egholm, M., et al., Nature **365**(6446): 566-8, (1993).
Feldmann, H., et al., Nat Rev Immunol **3**(8): 677-85, (2003).
25 Feldmann, H. and Kiley, M.P., Curr Top Microbiol Immunol **235**: 1-21, (1999).
Feldmann, H., et al., Arch Virol Suppl **7**: 81-100, (1993).
Felgner, P.L., et al., Proc Natl Acad Sci USA **84**(21): 7413-7, (1987).
Gait, M.J., et al., J Chem Soc [Perkin 1] **0**(14): 1684-6, (1974).
Gee, J.E., et al., Antisense Nucleic Acid Drug Dev **8**(2): 103-11, (1998).
30 Geisbert, T.W. and Hensley, L.E., Expert Rev Mol Med **6**(20): 1-24, (2004).
Geisbert, T.W., et al., Lancet **362**(9400): 1953-8, (2003).
Jahrling, P.B., et al., J Infect Dis **179** **Suppl 1**: S224-34, (1999).
Lesnikowski, Z.J., et al., Nucleic Acids Res **18**(8): 2109-15, (1990).
Mertes, M.P. and Coats, E.A., J Med Chem **12**(1): 154-7, (1969).

- Moulton, H. M., et al., Bioconjug Chem **15**(2): 290-9, (2004).
- Nelson, M. H., et al., Bioconjug Chem **16**(4): 959-66, (2005).
- Peters, C.J. and LeDuc, J.W., J Infect Dis **179 Suppl 1**: ix-xvi, (1999).
- Sanchez, A., et al., Virus Res **29**(3): 215-40, (1993).
- 5 Strauss, J.H. and Strauss, E.G., VIRUSES AND HUMAN DISEASE. San Diego, Academic Press, (2002).
- Summerton, J. and Weller, D., Antisense Nucleic Acid Drug Dev **7**(3): 187-95, (1997).
- Toulme, J. J., et al., Biochimie **78**(7): 663-73, (1996).
- 10 Warfield, K. L., et al., J Exp Med **200**(2): 169-79, (2004).

Background of the Invention

Minus-strand (-) RNA viruses are major causes of human suffering that cause epidemics of serious human illness. In humans the diseases caused by these viruses include influenza (Orthomyxoviridae), mumps, measles, upper and lower respiratory tract disease
15 (Paramyxoviridae), rabies (Rhabdoviridae), hemorrhagic fever (Filoviridae, Bunyaviridae and Arenaviridae), encephalitis (Bunyaviridae) and neurological illness (Bornaviridae). Virtually the entire human population is thought to be infected by many of these viruses (e.g. respiratory syncytial virus) (Strauss and Strauss 2002).

20 The order *Mononegavirales* is composed of four minus strand RNA virus families, the Rhabdoviridae, the Paramyxoviridae, the Filoviridae and the Bornaviridae. The viruses in these families contain a single strand of non-segmented negative-sense RNA and are responsible for a wide range of significant diseases in fish, plants, and animals. Viruses with segmented (-) RNA genomes belong to the Arenaviridae, Bunyaviridae and
25 Orthomyxoviridae families and possess genomes with two, three and seven or eight segments, respectively.

The expression of the five to ten genes encoded by the members of the *Mononegavirales* is controlled at the level of transcription by the order of the genes on the genome relative to the single 3' promoter. Gene order throughout the *Mononegavirales* is
30 highly conserved. Genes encoding products required in stoichiometric amounts for replication are always at or near the 3' end of the genome while those whose products are needed in catalytic amounts are more promoter distal (Strauss and Strauss 2002). The segmented (-) RNA viruses encode genes with similar functions to those encoded by the

Mononegavirales. Other features of virion structure and replication pathways are also shared among the (-) RNA viruses.

For some (-) RNA viruses, effective vaccines are available (e.g. influenza, mumps and measles virus) whereas for others there are no effective vaccines (e.g. Ebola virus and Marburg virus). In general, no effective antiviral therapies are available to treat an infection by any of these viruses. As with many other human viral pathogens, available treatment involves supportive measures such as anti-pyretics to control fever, fluids, antibiotics for secondary bacterial infections and respiratory support as necessary.

The development of a successful therapeutic for filoviruses Ebola and Marburg virus is a long-sought and seemingly difficult endeavor (Geisbert and Hensley 2004). Although they cause only a few hundred deaths worldwide each year, filoviruses are considered a significant world health threat and have many of the characteristics commonly associated with biological weapons since they can be grown in large quantities, can be fairly stable, are highly infectious as an aerosol, and are exceptionally deadly (Borio, Inglesby, et al. 2002). Filoviruses are relatively simple viruses of 19 Kb genomes and consist of seven genes which encode nucleoprotein (NP), glycoprotein (GP), four smaller viral proteins (VP24, VP30, VP35 and VP40), and the RNA-dependent RNA polymerase (L protein) all in a single strand of negative-sensed RNA (Feldmann and Kiley 1999). The development of an effective therapeutic for Ebola virus has been hindered by a lack of reagents and a clear understanding of filovirus pathogenesis, disparity between animal models, and both the difficulty and danger of working with Ebola virus in biosafety level (BSL)-4 conditions (Geisbert and Hensley 2004; Burnett, Henchal et al. 2005). Administration of type I interferons, therapeutic vaccines, immune globulins, ribavirin, and other nucleoside analogues have been somewhat successful in rodent Ebola virus models, but not in infected nonhuman primates (Jahrling, Geisbert et al. 1999; Geisbert and Hensley 2004; Warfield, Perkins et al. 2004). Ebola virus frequently causes severe disseminated intravascular coagulation and administration of a recombinant clotting inhibitor has recently shown to protect 33% of rhesus monkeys (Geisbert, Hensley et al. 2003; Geisbert and Hensley 2004). Host-directed therapeutics alone have not proven to be a sufficiently efficacious therapeutic approach. A well-orchestrated sequence-specific attack on viral gene expression is required for a highly successful anti-filovirus therapeutic and treatment regimen.

In view of the severity of the diseases caused by (-) RNA viruses, in particular members of the Filoviridae family of viruses, and the lack of effective prevention or therapies, it is therefore an object of the present invention to provide therapeutic compounds and methods for treating a host infected with a (-) RNA virus.

5

Summary of the Invention

The invention includes, in one aspect, an anti-viral antisense composition effective in inhibiting replication within a host cell of an Ebola virus or Marburg virus. The composition contains one or more antisense compounds that target viral RNA sequences within a region of the positive-strand mRNA that includes the region 5' and/or the 25-
10 basepair region just downstream of the AUG start site of the (i) VP35 polymerase, (ii) the L polymerase, (iii) the VP24 membrane associated protein, (iv) the VP40 membrane-associated protein, and (v) the VP30 nucleoprotein. The antiviral compound(s) in the composition include an oligonucleotide analog having:


- 15 a) a nuclease-resistant backbone,
 b) 15-40 nucleotide bases, and
 c) a targeting sequence of at least 15 bases in length that hybridizes to a target region selected from the following:
- i) the AUG start site region of VP35, as exemplified by antisense
20 compounds SEQ ID NOs:21-26,
 ii) the AUG start site region of VP24, as exemplified by antisense compound SEQ ID NO:34,
 iii) the region 85 to 65 base pairs upstream of the AUG start site of VP24, as exemplified by SEQ ID NO:39,
25 iv) the AUG start site region of polymerase L, as exemplified by antisense compound SEQ ID NO:17, and
 v) combinations of (i), (ii), (iii) and/or (iv).

The oligonucleotide analog also has:

- 30 a) the capability of being actively taken up by mammalian host cells, and
 b) the ability to form a heteroduplex structure with the viral target region, wherein said heteroduplex structure is:
- i) composed of the positive or negative sense strand of the virus and the oligonucleotide compound, and

ii) characterized by a T_m of dissociation of at least 45°C.

The compound may be composed of morpholino subunits linked by uncharged, phosphorus-containing intersubunit linkages, joining a morpholino nitrogen of one subunit to a 5' exocyclic carbon of an adjacent subunit. In one embodiment, the intersubunit linkages are phosphorodiamidate linkages, such as those having the structure:



where $Y_1=O$, $Z=O$, P_j is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is alkyl, alkoxy, thioalkoxy, or alkyl amino *e.g.*, wherein $X=NR_2$, where each R is independently hydrogen or methyl. The compound may contain one or more cationic linkages wherein $X=(1-$
10 piperazino).

The compound may also be a covalent conjugate of an oligonucleotide analog moiety capable of forming such a heteroduplex structure with the positive or negative sense strand of the virus, and an arginine-rich polypeptide effective to enhance the uptake
15 of the compound into host cells. Exemplary polypeptides have one of the sequences identified as SEQ ID NOs:61-66.

Exemplary compositions include one or more antisense compounds that target a positive strand RNA region that includes:

(i) the AUG start site region of VP35, as exemplified by antisense compounds SEQ
20 ID NOs:21-26,

(ii) the AUG start site region of VP24, as exemplified by antisense compound SEQ
ID NO:34,

(iii) the region 85 to 65 base pairs upstream of the AUG start site of VP24, as
exemplified by SEQ ID NO:39,

(iv) the AUG start site region of polymerase L, as exemplified by antisense
25 compound SEQ ID NO:17, and

(v) combinations of (i), (ii), (iii) and/or (iv).

The antisense compound(s) in the composition preferably target(s) at least 18, more preferably, at least 20 target base pairs.

In another aspect, the invention includes a method of treating an Ebola or Marburg virus infection in a mammalian host, by administering to the host, a therapeutically effective amount of a composition of the type described above. The method includes, in exemplary embodiments, administering a composition having a combination of antisense compounds targeted against different viral proteins, such as the VP35, VP24, and L polymerase proteins.

In a related, more general aspect, the invention includes a method of vaccinating a mammalian subject against Ebola or Marburg virus by pretreating the subject with the composition of the invention, and exposing the subject to the Ebola virus, preferably in an attenuated form.

These and other objects and features of the invention will become more fully apparent when the following detailed description of the invention is read in conjunction with the accompanying drawings.

Brief Description of the Figures

Figures 1A-1D show the repeating subunit segment of several preferred morpholino oligonucleotides, designated A through D, constructed using subunits having 5-atom (A), six-atom (B) and seven-atom (C-D) linking groups suitable for forming polymers.

Figs. 2A-2G show the backbone structures of various oligonucleotide analogs with uncharged backbones and Fig. 2H shows a cationic linkage structure.

Figs. 3A-3C illustrate the components and morphology of a filovirus (3A), and show the arrangement of viral genes in the Ebola virus (Zaire) (3B), and the Marburg virus (3C).

Figs. 4A-4B show the target regions of 6 antisense compounds targeted against the VP35 gene in Ebola virus.

Fig. 5 is a plot showing cytotoxicity in Vero cell culture, expressed as a percent control, as a function of antisense type and concentration.

Figs. 6A-6C are photomicrographs of Vero cells in culture (6A) in the absence of Ebola virus infection and antisense treatment; (6B) with Ebola virus infection but no antisense treatment; and (6C) with Ebola virus infection and treatment with VP35-AUG (SEQ ID NO:17) antisense compound.

Fig. 7 is a plot of treatment efficacy, expressed as a fraction of mouse survivors 10 days post infection, as a function of VP35 antisense length.

Fig. 8 is a plot of treatment efficacy, expressed as percent survival, as a function of dose of various combinations of antisense compounds.

5 Figs. 9A shows the schedule of the experimental protocol. Fig. 9B plots the fraction of mouse survivors with various dose schedules of antisense compounds.

Fig. 10 is a schematic of the treatment schedule for a trial using PMO to treat Ebola infection in nonhuman primates.

Fig. 11 shows Ebola-specific PMOs protect mice from lethal Ebola virus infection.
 10 (A) Survival of mice pretreated at 4 and 24 hours before EBOV infection with 500 µg of PMOs targeting VP24 (◆), VP35 (■), L (▲), or with an unrelated sequence (×). (B) Survival of mice pretreated with 1 mg (◇), 0.1 mg (□), or 0.01 mg (△) of a combination of the VP24, VP35, and L PMOs or 1 mg (◆), 0.1 mg (■), or 0.01 mg (▲) of VP35 PMO only or an unrelated sequence (×). (C) Survival in mice treated 24 hours following
 15 EBOV infection with 1 mg (◆), 0.1 mg (■), or 0.01 mg (▲) of the combination of PMOs or an unrelated sequence (×). (D - G) C57Bl/6 mice were challenged intraperitoneally with 1000 plaque-forming units of EBOV following treatment with PMOs. Immunoperoxidase stain is brown with hematoxylin counterstain. Viral antigen within the spleen (100X) of a mouse treated with scrambled PMO (D) or the EBOV PMOs (E) three
 20 days after EBOV infection. Diffuse staining pattern in the livers (600X) of the scrambled PMO-treated mice (F) on day 6 of EBOV infection, compared to focal areas of infection in the mice treated with the combination of PMOs (G).

Fig. 12 shows that treatment of guinea pigs with antisense PMOs increases survival following lethal Ebola virus infection. Hartley guinea pigs were treated intraperitoneally
 25 with 10 mg each of VP24, VP35, and L PMO in PBS at -24 (▲), +24 (●), or +96 (■) hours post challenge. Control guinea pigs were injected with PBS only (×). The guinea pigs were infected subcutaneously with ~1000 pfu of EBOV and monitored for illness for 21 days. The data are presented as percent survival for each group (n=6).

Fig. 13 shows that Ebola-specific PMOs reduce viral replication *in vivo*. Viral
 30 titers in tissues from mice treated with a combination of PMO and infected with 1000 pfu of EBOV. Samples of the liver, spleen, and kidney were taken at 3 or 6 days post challenge (dpc), macerated, and analyzed for viral titer using plaque assay. The data are

presented as the mean viral titer of 3 mice with error bars representing the standard deviation.

Fig. 14 shows the immune responses of PMO-treated mice following survival of Ebola virus infection. (A) PMO-treated C57BL/6 mice that have previously survived EBOV infection generate EBOV-specific CD8⁺ responses. Pooled splenocytes from three PMO-treated EBOV survivors were re-stimulated *in vitro* with EBOV-specific VP35 or NP peptides, an irrelevant Lassa NP peptide as a negative control, or PMA/ionomycin as a positive control. The stimulated cells were stained after for 4 hours in culture with anti-CD44 FITC, anti-IFN- γ PE, and anti-CD8 Cy-Chrome. The percent of CD44⁺, IFN- γ ⁺ cells among CD8⁺ lymphocytes is indicated in the upper right quadrant of each plot. These data are representative of the Ebola CD8 specific epitopes observed after challenge. (B) Total serum anti-Ebola virus antibodies were measured in surviving mice prior to or 4 weeks following treatment and challenge. PMO mice were treated with the combination of PMOs 24 and 4 hours before challenge and their antibody responses are compared with mice treated with Ebola VLPs 24 hours before EBOV infection. The results are depicted as the endpoint titers of the individual mice (circles). The horizontal line in each column represents the geometric mean titer of the group. (C) Mice that previously survived EBOV challenge following PMO treatment were re-challenged with 1000 pfu of mouse-adapted Ebola virus 4 weeks after the initial challenge. Results are plotted as percent survival for the PMO-treated mice (black) and naïve control mice (n=10 per group).

Fig. 15 shows that treatment of rhesus macaques with antisense PMOs provide protection against lethal Ebola virus infection. (A) Survival following infection with 1000 pfu of EBOV in monkeys treated with a combination of PMOs (■) or untreated monkeys (○). The arrows indicate the monkeys that died at the time indicated. (B-D) Viral titers (B), platelet counts (C), or alkaline phosphatase levels (D) in the blood of the PMO-treated monkeys [0646 (◆), 1438 (▲), 1496 (×), 1510 (■)] or an untreated monkey (○).

Fig. 16 shows the increased antisense activity of PMOs with cationic linkages targeting the EBOV VP24 mRNA in a cell free translation assay. PMOs used were 537-AUG (SEQ ID NO:34), 164-AUG+ (SEQ ID NO:40), 165-5'-term (SEQ ID NO:39) and 166-5'-term+ (SEQ ID NO:41).

Detailed Description of the Invention

I. Definitions

The terms below, as used herein, have the following meanings, unless otherwise indicated:

5 The terms "oligonucleotide analog" refers to an oligonucleotide having (i) a modified backbone structure, *e.g.*, a backbone other than the standard phosphodiester linkage found in natural oligo- and polynucleotides, and (ii) optionally, modified sugar moieties, *e.g.*, morpholino moieties rather than ribose or deoxyribose moieties. The analog supports bases capable of hydrogen bonding by Watson-Crick base pairing to standard
10 polynucleotide bases, where the analog backbone presents the bases in a manner to permit such hydrogen bonding in a sequence-specific fashion between the oligonucleotide analog molecule and bases in a standard polynucleotide (*e.g.*, single-stranded RNA or single-stranded DNA). Preferred analogs are those having a substantially uncharged, phosphorus containing backbone.

15 A substantially uncharged, phosphorus containing backbone in an oligonucleotide analog is one in which a majority of the subunit linkages, *e.g.*, between 60-100%, are uncharged at physiological pH, and contain a single phosphorous atom. The analog contains between 8 and 40 subunits, typically about 8-25 subunits, and preferably about 12 to 25 subunits. The analog may have exact sequence complementarity to the target
20 sequence or near complementarity, as defined below.

A "subunit" of an oligonucleotide analog refers to one nucleotide (or nucleotide analog) unit of the analog. The term may refer to the nucleotide unit with or without the attached intersubunit linkage, although, when referring to a "charged subunit", the charge typically resides within the intersubunit linkage (*e.g.* a phosphate or phosphorothioate
25 linkage).

A "morpholino oligonucleotide analog" is an oligonucleotide analog composed of morpholino subunit structures of the form shown in Figs. 1A-1D, where (i) the structures are linked together by phosphorus-containing linkages, one to three atoms long, joining the morpholino nitrogen of one subunit to the 5' exocyclic carbon of an adjacent subunit, and
30 (ii) P_i and P_j are purine or pyrimidine base-pairing moieties effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide. The purine or pyrimidine base-pairing moiety is typically adenine, cytosine, guanine, uracil, thymine or inosine. The synthesis, structures, and binding characteristics of morpholino oligomers are detailed in

U.S. Patent Nos. 5,698,685, 5,217,866, 5,142,047, 5,034,506, 5,166,315, 5,521,063, and 5,506,337, all of which are incorporated herein by reference.

The subunit and linkage shown in Figure 1B are used for six-atom repeating-unit backbones, as shown in Figure 1B (where the six atoms include: a morpholino nitrogen, the connected phosphorus atom, the atom (usually oxygen) linking the phosphorus atom to the 5' exocyclic carbon, the 5' exocyclic carbon, and two carbon atoms of the next morpholino ring). In these structures, the atom Y₁ linking the 5' exocyclic morpholino carbon to the phosphorus group may be sulfur, nitrogen, carbon or, preferably, oxygen. The X moiety pendant from the phosphorus is any stable group which does not interfere with base-specific hydrogen bonding. Preferred X groups include fluoro, alkyl, alkoxy, thioalkoxy, and alkyl amino, including cyclic amines, all of which can be variously substituted, as long as base-specific bonding is not disrupted. Alkyl, alkoxy and thioalkoxy preferably include 1-6 carbon atoms. Alkyl amino preferably refers to lower alkyl (C₁ to C₆) substitution, and cyclic amines are preferably 5- to 7-membered nitrogen heterocycles optionally containing 1-2 additional heteroatoms selected from oxygen, nitrogen, and sulfur. Z is sulfur or oxygen, and is preferably oxygen.

A preferred morpholino oligomer is a phosphorodiamidate-linked morpholino oligomer, referred to herein as a PMO. Such oligomers are composed of morpholino subunit structures such as shown in Fig. 1B, where X=NH₂, NHR, or NR₂ (where R is lower alkyl, preferably methyl), Y=O, and Z=O, and P_i and P_j are purine or pyrimidine base-pairing moieties effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide. Also preferred are structures having an alternate phosphorodiamidate linkage, where, in Fig. 1B, X = lower alkoxy, such as methoxy or ethoxy, Y=NH or NR, where R is lower alkyl, and Z=O. A cationic linkage can be introduced into the backbone by utilizing X= (1-piperazino) as shown in Fig. 1B.

The term "substituted", particularly with respect to an alkyl, alkoxy, thioalkoxy, or alkylamino group, refers to replacement of a hydrogen atom on carbon with a heteroatom-containing substituent, such as, for example, halogen, hydroxy, alkoxy, thiol, alkylthio, amino, alkylamino, imino, oxo (keto), nitro, cyano, or various acids or esters such as carboxylic, sulfonic, or phosphonic. It may also refer to replacement of a hydrogen atom on a heteroatom (such as an amine hydrogen) with an alkyl, carbonyl or other carbon containing group.

As used herein, the term "target", relative to the viral genomic RNA, refers to at least one of the following: 1) a 125 nucleotide region that surrounds the AUG start codon of a viral messenger RNA and/or; 2) the terminal 30 bases of the 3' terminal end of the minus-strand viral RNA (*e.g.* virion RNA or vRNA) and/or; 3) the terminal 25 bases of viral mRNA transcripts

The term "target sequence" refers to a portion of the target RNA against which the oligonucleotide analog is directed, that is, the sequence to which the oligonucleotide analog will hybridize by Watson-Crick base pairing of a complementary sequence. As will be seen, the target sequence may be a contiguous region of the viral positive-strand mRNA or the minus-strand vRNA.

The term "targeting sequence" is the sequence in the oligonucleotide analog that is complementary (meaning, in addition, substantially complementary) to the target sequence in the RNA genome. The entire sequence, or only a portion, of the analog compound may be complementary to the target sequence. For example, in an analog having 20 bases, only 12-14 may be targeting sequences. Typically, the targeting sequence is formed of contiguous bases in the analog, but may alternatively be formed of non-contiguous sequences that when placed together, *e.g.*, from opposite ends of the analog, constitute a sequence that spans the target sequence. For example, as will be seen, the target and targeting sequences are selected such that binding of the analog to a portion of a 125 nucleotide region associated with the AUG start codon of the positive-sense RNA strand (*i.e.*, mRNA) of the virus acts to disrupt translation of the viral gene and reduce viral replication.

The term "AUG start site region" includes a 125 nucleotide region in both the 5' and 3' direction relative to the AUG start codon of viral mRNAs. The region includes about 25 nucleotides downstream (*i.e.*, in a 3' direction) and 100 nucleotides upstream (*i.e.*, in a 5' direction) as exemplified by the target sequences shown as SEQ ID NOs: 1-6 for Ebola virus and SEQ ID NOs: 8-13 for Marburg virus.

Target and targeting sequences are described as "complementary" to one another when hybridization occurs in an antiparallel configuration. A targeting sequence may have "near" or "substantial" complementarity to the target sequence and still function for the purpose of the present invention, that is, still be "complementary." Preferably, the oligonucleotide analog compounds employed in the present invention have at most one mismatch with the target sequence out of 10 nucleotides, and preferably at most one

mismatch out of 20. Alternatively, the antisense oligomers employed have at least 90% sequence homology, and preferably at least 95% sequence homology, with the exemplary targeting sequences as designated herein.

An oligonucleotide analog "specifically hybridizes" to a target polynucleotide if the oligomer hybridizes to the target under physiological conditions, with a T_m substantially greater than 45°C, preferably at least 50°C, and typically 60°C-80°C or higher. Such hybridization preferably corresponds to stringent hybridization conditions. At a given ionic strength and pH, the T_m is the temperature at which 50% of a target sequence hybridizes to a complementary polynucleotide. Again, such hybridization may occur with "near" or "substantial" complementarity of the antisense oligomer to the target sequence, as well as with exact complementarity.

A "nuclease-resistant" oligomeric molecule (oligomer) refers to one whose backbone is substantially resistant to nuclease cleavage, in non-hybridized or hybridized form; by common extracellular and intracellular nucleases in the body; that is, the oligomer shows little or no nuclease cleavage under normal nuclease conditions in the body to which the oligomer is exposed.

A "heteroduplex" refers to a duplex between an oligonucleotide analog and the complementary portion of a target RNA. A "nuclease-resistant heteroduplex" refers to a heteroduplex formed by the binding of an antisense oligomer to its complementary target, such that the heteroduplex is substantially resistant to *in vivo* degradation by intracellular and extracellular nucleases, such as RNaseH, which are capable of cutting double-stranded RNA/RNA or RNA/DNA complexes.

A "base-specific intracellular binding event involving a target RNA" refers to the specific binding of an oligonucleotide analog to a target RNA sequence inside a cell. The base specificity of such binding is sequence specific. For example, a single-stranded polynucleotide can specifically bind to a single-stranded polynucleotide that is complementary in sequence.

An "effective amount" of an antisense oligomer, targeted against an infecting filovirus, is an amount effective to reduce the rate of replication of the infecting virus, and/or viral load, and/or symptoms associated with the viral infection.

As used herein, the term "body fluid" encompasses a variety of sample types obtained from a subject including, urine, saliva, plasma, blood, spinal fluid, or other

sample of biological origin, such as skin cells or dermal debris, and may refer to cells or cell fragments suspended therein, or the liquid medium and its solutes.

The term "relative amount" is used where a comparison is made between a test measurement and a control measurement. The relative amount of a reagent forming a complex in a reaction is the amount reacting with a test specimen, compared with the amount reacting with a control specimen. The control specimen may be run separately in the same assay, or it may be part of the same sample (for example, normal tissue surrounding a malignant area in a tissue section).

"Treatment" of an individual or a cell is any type of intervention provided as a means to alter the natural course of the individual or cell. Treatment includes, but is not limited to, administration of *e.g.*, a pharmaceutical composition, and may be performed either prophylactically, or subsequent to the initiation of a pathologic event or contact with an etiologic agent. The related term "improved therapeutic outcome" relative to a patient diagnosed as infected with a particular virus, refers to a slowing or diminution in the growth of virus, or viral load, or detectable symptoms associated with infection by that particular virus.

An agent is "actively taken up by mammalian cells" when the agent can enter the cell by a mechanism other than passive diffusion across the cell membrane. The agent may be transported, for example, by "active transport", referring to transport of agents across a mammalian cell membrane by *e.g.* an ATP-dependent transport mechanism, or by "facilitated transport", referring to transport of antisense agents across the cell membrane by a transport mechanism that requires binding of the agent to a transport protein, which then facilitates passage of the bound agent across the membrane. For both active and facilitated transport, the oligonucleotide analog preferably has a substantially uncharged backbone, as defined below. Alternatively, the antisense compound may be formulated in a complexed form, such as an agent having an anionic backbone complexed with cationic lipids or liposomes, which can be taken into cells by an endocytotic mechanism. The analog also may be conjugated, *e.g.*, at its 5' or 3' end, to an arginine-rich peptide, *e.g.*, a portion of the HIV TAT protein, or polyarginine, to facilitate transport into the target host cell as described (Moulton, Nelson *et al.* 2004). The compound may also have one or more cationic linkages to enhance antisense activity and/or cellular uptake. A preferred cationic linkage is shown in Fig. 1B where X= (1-piperazino).

The term "filovirus" refers collectively to members of the Filoviridae family of single stranded (-) RNA viruses including Ebola and Marburg viruses listed in Table 1 below.

5 II. Targeted Viruses

The present invention is based on the discovery that effective inhibition of single-stranded, negative-sense RNA ((-) RNA)viruses can be achieved by exposing cells infected with the virus to antisense oligonucleotide analog compounds (i) targeted against the AUG start codon of the positive sense viral mRNAs or the 3' terminus of the negative strand viral RNA, and (ii) having physical and pharmacokinetic features which allow effective interaction between the antisense compound and the virus within host cells. In one aspect, the oligomers can be used in treating a mammalian subject infected with the virus.

The invention targets RNA viruses having genomes that are: (i) single stranded, (ii) negative polarity, and (iii) less than 20 kb. The targeted viruses also synthesize a RNA species with positive polarity, the positive-strand or sense RNA, as the requisite step in viral gene expression. In particular, targeted viruses include those of the Filoviridae family referred to herein as filoviruses. Targeted viruses organized by family, genus and species are listed in Table 1. Various physical, morphological, and biological characteristics of each of the Filoviridae family, and members therein, can be found, for example, in Textbook of Human Virology, R. Belshe, ed., 2nd Edition, Mosby, 1991, in "Viruses and Human Disease" (Strauss and Strauss 2002) and at the Universal Virus Database of the International Committee on Taxonomy of Viruses (www.ncbi.nlm.nih.gov/ICTVdb/index.htm). Some of the key biological characteristics of each family are summarized below following Table 1.

25

TABLE 1. Targeted viruses of the invention organized by family and genus

Family	Genus	Virus
Filoviridae	<i>Marburg-like</i>	Marburg virus (MARV)
	<i>Ebola-like</i>	Zaire Ebola virus (ZEBOV)
		Sudan Ebola virus (SEBOV)
		Reston Ebola virus (REBOV)
		Cote d'Ivoire Ebola (ICEBOV)

A. Filoviridae

The Filoviridae family is composed of two members, Ebola virus (EBOV) and Marburg virus (MARV). Four species of Ebola have been identified to date and are named by the location of where they were identified including Ebola Ivory Coast (ICEBOV),
 5 Ebola Zaire (ZEBOV), Ebola Sudan (SEBOV) and Ebola Reston (REBOV). Ebola Reston is the only known filovirus that does not cause severe human disease. The filovirus structure is pleomorphic with shapes varying from long filaments to shorter contorted structures. The viral filaments measure up to 14,000 nm in length and have uniform diameter of 80 nm. The virus filament is envelope in a lipid membrane. The virion
 10 contains one, single-stranded, negative sense RNA.

The first filovirus was recognized in 1967 after laboratory workers in Marburg Germany developed hemorrhagic fever following studies involving handling tissues from green monkeys. The Marburg outbreak led to 31 cases and seven deaths. The first Ebola virus was identified in 1976 following outbreaks of Ebola hemorrhagic fever in northern
 15 Zaire (now the Democratic Republic of Congo) and southern Sudan. Eventually, two distinct viral isolates were recognized. Ebola Zaire was lethal in 90% of the infected cases and Ebola Sudan was lethal in 50% of the cases. A list of Ebola hemorrhagic fever cases is compiled for Ebola Zaire in TABLE 2.

20

TABLE 2. Chronological order of Ebola Zaire Outbreaks

Date	Location	Human Cases	Deaths
1976	Zaire	318	280 (88%)
1977	Zaire	1	1 (100%)
1994	Gabon	49	29 (59%)
1995	Dem. Rep. Congo	315	255 (81%)
1996	Gabon	31	21 (68%)
1996	Gabon	60	45 (75%)
1996	South Africa	2	1 (50%)
2001	Gabon and Congo	122	96 (79%)

The summary of these outbreak data include 899 cases resulting in 728 deaths or an
 25 overall 81% rate of lethality observed over a period of 25 years. A single case of Ebola Ivory Coast was reported in 1994 and that infection was not lethal. Finally, 4 outbreaks of Ebola Sudan from 1976 to 2001 produced 744 cases resulting in 398 deaths or an overall rate of lethality of 53%. These observations indicate Ebola Zaire is the virus of greatest

concern both in apparent prevalence and lethality. It appears Ebola is transmitted to humans from ongoing life cycles in animals other than humans which make it a zoonotic virus. Ebola can replicate in various rodents such as mice, guinea pigs and some species of bats. Some types of bats are native to areas where the virus is found which suggests the bat
5 may be the natural host and viral reservoir. Once a human is infected, person-to-person transmission is the means for further infections. During recorded outbreaks, individuals that cared for or worked closely with infected people were at high risk of becoming infected. Nosocomial transmission has also been an important factor in the spread of viral infection during outbreaks. In the laboratory setting, viral spread through small-particle
10 aerosols has been clearly demonstrated.

The incubation period for Ebola hemorrhagic fever ranges from 2 to 21 days. The clinical symptoms include abrupt onset of fever, headache, joint and muscle aches, sore throat and weakness. These symptoms are then followed by diarrhea, vomiting and stomach pain which do not help in diagnosis of infection. Diagnosis is suspected when this
15 group of symptoms is observed in an area where Ebola is known to be active. Patients who die usually have not developed a significant immune response to the virus at the time of death. There are no known treatments for filovirus infections.

The filovirus virus genome is approximately 19,000 bases of single-stranded RNA that is unsegmented and in the antisense (i.e. negative sense) orientation. The genome
20 encodes 7 proteins from monocistronic mRNAs complementary to the vRNA as shown in Figure 3. A review of filoviruses can be found in *Fields Virology and (Strauss and Strauss 2002)*.

Ebola virus

Ebola virus (EBOV), a member of the family *Filoviridae* and the order
25 Mononegavirales, is an enveloped, nonsegmented negative-strand RNA virus and is one of the most lethal human and nonhuman primate pathogens recognized to date. Four subtypes of Ebola virus have been identified, including Zaire (ZEBOV), Sudan (SEBOV), Ivory Coast (ICEBOV), and Reston (REBOV) (Sanchez, Kiley *et al.* 1993). Human infection with subtype Zaire causes a fulminating, febrile, hemorrhagic disease resulting in extensive
30 mortality (Feldmann, Klenk *et al.* 1993; Peters and LeDuc 1999; Feldmann, Jones *et al.* 2003).

Ebola virus particles have a filamentous appearance, but their shape may be branched, circular, U- or 6-shaped, or long and straight. Virions show a uniform diameter

of approximately 80 nm, but vary greatly in length. Ebola virus particles consist of seven structural proteins. The glycoprotein (GP) of Ebola virus forms spikes of approximately 7 nm, which are spaced at 5- to 10-nm intervals on the virion surface.

Marburg virus

5 Marburg virus (MARV) was first recognized in 1967, when an outbreak of hemorrhagic fever in humans occurred in Germany and Yugoslavia, after the importation of infected monkeys from Uganda. Thirty-one cases of MARV hemorrhagic fever were identified that resulted in seven deaths. The filamentous morphology of the virus was later recognized to be characteristic, not only of additional MARV isolates, but also of EBOV.
10 MARV and EBOV are now known to be distinctly different lineages in the family Filoviridae, within the viral order Mononegavirales (Strauss and Strauss 2002).

Few natural outbreaks of MARV disease have been recognized, and all proved self-limiting, with no more than two cycles of human-to-human transmission. However, the actual risks posed by MARV to global health cannot be assessed because factors which
15 restrict the virus to its unidentified ecological niche in eastern Africa, and those that limit its transmissibility, remain unknown. Concern about MARV is further heightened by its known stability and infectivity in aerosol form. A recent (2005) epidemic in eastern Africa caused at least 200 deaths and further increases the concern about MARV.

20 B. Target Sequences

The filovirus structure is pleomorphic with shapes varying from long filaments to shorter contorted structures. The viral filaments measure up to 14,000 nm in length and have uniform diameter of 80 nm. The virus filament is envelope in a lipid membrane. The virion contains one, single-stranded, negative sense RNA. The filovirus virus genome is
25 approximately 19,000 bases of single- stranded RNA that is unsegmented and in the antisense orientation. The genome encodes 7 proteins from monocistronic mRNAs complementary to the vRNA. A diagram of a representative filovirus and its genome is provided in Figs. 3A-3C (taken from Fields Virology).

The targets selected were positive-strand (sense) RNA sequences that span or are
30 just downstream (within 25 bases) or upstream (within 100 bases) of the AUG start codon of selected Ebola virus proteins or the 3' terminal 30 bases of the minus-strand viral RNA. Preferred protein targets are the viral polymerase subunits VP35 and L, nucleoproteins NP and VP30, and membrane-associated proteins VP24 and VP40. Among these early

proteins are favored, *e.g.*, VP35 is favored over the later expressed L polymerase. As will be seen, a preferred single-compound target is VP35 that spans the AUG start site, and/or targets a region within 100 bases upstream or 25 bases downstream of the translational start site. Preferred combinations of targets include the VP35-AUG target plus the VP24-AUG start site (or the 100-base region upstream or 25-base-region downstream of the start site) and or the L polymerase AUG start site (or the 100-base region upstream or 25-base-region downstream of the start site).

Additional targets include the terminal 25 base pair region of the viral mRNA transcripts as represented by the sequences complementary to the SEQ ID NOs:42 and 43. These targets are preferred because of their high degree of sequence conservation across individual filovirus isolates.

The Ebola virus RNA sequences (Zaire Ebola virus, Mayinga strain) can be obtained from GenBank Accession No. AF086833. The particular targeting sequences shown below were selected for specificity against the Ebola Zaire virus strain.

Corresponding sequences for Ebola Ivory Coast, Ebola Sudan and Ebola Reston (GenBank Acc. No. AF522874) are readily determined from the known GenBank entries for these viruses. Preferably targeting sequences are selected that give a maximum consensus among the viral strains, particularly the Zaire, Ivory Coast, and Sudan strains, or base mismatches that can be accommodated by ambiguous bases in the antisense sequence, according to well-known base pairing rules.

GenBank references for exemplary viral nucleic acid sequences representing filovirus genomic segments are listed in Table 3 below. The nucleotide sequence numbers in Table 3 are derived from the GenBank reference for the positive-strand RNA of Ebola Zaire (AF086833) and Marburg virus (Z29337). It will be appreciated that these sequences are only illustrative of other sequences in the Filoviridae family, as may be available from available gene-sequence databases of literature or patent resources (See *e.g.* www.ncbi.nlm.nih.gov). The sequences in Table 3 below, identified as SEQ ID NOs:1-14, are also listed in the Sequence Listing table at the end of the specification.

The target sequences in Table 3 represent the 3' terminal 30 bases of the negative sense viral RNA or the 125 bases surrounding the AUG start codons of the indicated filovirus genes. The sequences shown are the positive-strand (*i.e.*, antigenomic or mRNA) sequence in the 5' to 3' orientation. It will be obvious that when the target is the minus-

strand vRNA, as in the case of the Str Inh 1 target (SEQ ID NOs:15 and 44) the targeted sequence is the complement of the sequence listed in Table 3 .

Table 3 lists the targets for exemplary Ebola viral genes VP35, VP24, VP30, VP40, L and NP. The proteins represent six of the seven proteins encoded by Ebola. The target
5 sequences for the AUG start codons of the six genes are represented as SEQ ID NOs:1-6. The corresponding set of target sequences for Marburg virus are shown as SEQ ID NOs:8-13. The 3' terminal sequence of the minus-strand viral RNA (SEQ ID NOs:7 and 14) can also be targeted. The sequences shown in Table 3 for the 3' terminal minus-strand targets (SEQ ID NOs:7 and 14) are the minus-strand sequences in a 5'-3' orientation for Ebola and
10 Marburg viruses, respectively.

TABLE 3. Exemplary Filovirus Nucleic Acid Target Sequences

Name	GenBank No.	Nucleotide Region	Sequence (5' to 3')	SEQ ID NO
VP35-AUG	AF086833	3029-3153	AAUGAUGAAGAUUAAAACCUUCAUCAU CCUUACGUCAAUUGAAUUCUCUAGCAC UCGAAGCUUAUUGUCUUCAAUGUAAAA GAAAAGCUGGUCUAACAAGAUGACAAC UAGAACAAGGGCAGGG	1
VP24-AUG	AF086833	10245-10369	CGUUCCAACA AUCGAGCGCAAGGUUCA AGGUUGAACU GAGAGUGUCUAGACAACA AAUAUUGAU ACUCCAGACACCAAGCAA GACCUGAGAA AAAACC AUGGCUAAAAGCU ACGGGACGAU ACA	2
VP30-AUG	AF086833	8409-8533	AGAUCUGCGA ACCGGUAGAGUUUAGUUG CAACCUAACA CACAUAAGCAUUGGUCA AAAAGUCAAU AGAAAUUUAAACAGUGAG UGGAGACAAC UUUUAAAUGGAAGCUUCA UAUGAGAGAG GAC	3
VP40-AUG	AF086833	4379-4503	AAACCAAAAG UGAUGAAGAUUAAGAAAA ACCUACCUCG GCUGAGAGAGUGUUUUUU CAUUAACCUU CAUCUUGUAAACGUUGAG CAAAUUGUU AAAAAU AUGAGGCGGGUU AUUUGCCUA CUG	4
L-AUG	AF086833	11481-11605	GUAGAUUAAAG AAAAAAGCCUGAGGAAGA UUAAGAAAAA CUGCUUAUUGGGUCUUUC CGUGUUUAG AUGAAGCAGUUGAAAUUC UUCCUCUUGA UAUUAAAUGGCUACACAA CAUACCCAUA C	5
NP-AUG	AF086833	370-494	UGAACACUUA GGGGAUUGAAGAUUCAAC AACCCUAAAG CUUGGGGUAAAACAUUGG AAAUAGUUA AAAGACAAAUUGCUCGGAA UCACAAAAU UCCGAGUAUGGAUUCUCGU CCUCAGAAAUCU	6
Str. Ihn 1 (-)	AF086833	30-1	UAAAAAUUCUUCUUCUUUUUGUGUGU CCG	7
VP35-AUG	Z29337	2844-2968	CUAAAAUCGAAGAAUUAUAAAGGUUUU CUUUAAUAUUCAGAAAAGGUUUUUUAU CUCUUCUUUCUUUUUGCAAACAUAUUGA AAUAAUAAU UUCACA AUGUGGGACUCA UCAUAUAUGCAAC	8
VP24-AUG	Z29337	10105-10229	UUCAUUCAAACACCCCAAUUUUCAAUC AUACACAUAUAACCAUUUUAGUAGCGU UACCUUUCAAUACAAUCUAGGUGAUUGU GAAAAGACU UCCAAAC AUGGCAGAAUUA UCAACGCGUACA	9

Name	GenBank No.	Nucleotide Region	Sequence (5' to 3')	SEQ ID NO
VP30-AUG	Z29337	8767-8891	GAAGAACAUUAAGUGUUCUUUGUUAGAA UUAUUCAUCCAAGUUGUUUUGAGUAUAC UCGCUUCAAUACAACUCCCUUCAUAAU UGAUUCAAGAUUUAAAUGCAACAACCC CGUGGAAGGAGU	10
VP40-AUG	Z29337	4467-4591	UCCCAAUCUCAGCUUGUUGAAUUAUUG UUACUUAAGUCAUUCUUUUUAAAUAUAA UUCACACAAGGUAGUUUGGGUUUAUAC UAGAACA AAUUUUAUUAUGGCCAGUCC AGCAAUUACAACA	11
L-AUG	Z29337	11379-11503	UCAUUCUCUUCGAUACACGUUAUAUCUU UAGCAAAGUAAUGAAAAUAGCCUUGUCA UGUUAGACGCCAGUUAUCCAUCUUAAGU GAAUCCUUUCUCAAUAUGCAGCAUCCA ACUCAUAUCCUG	12
NP-AUG	Z29337	3-127	CACACAAAACAAGAGAUGAUGAUUUUG UGUAUCAUUAUUAAUAAAGAAGAAUUA ACAUUGACAUUGAGACUUGUCAGUCUGU UAAUAUUCUUGAAAAGAUGGAUUUACAU AGCUUGUUAGAGU	13
Str. I hn 1 (-)	Z29337	30-1	CAAAUCAUCAUCUCUUGUUUUUGUGU GUC	14

Targeting sequences are designed to hybridize to a region of the target sequence as listed in Table 3. Selected targeting sequences can be made shorter, *e.g.*, 12 bases, or longer, *e.g.*, 40 bases, and include a small number of mismatches, as long as the sequence is sufficiently complementary to allow hybridization with the target, and forms with either the virus positive-strand or minus-strand, a heteroduplex having a T_m of 45°C or greater.

More generally, the degree of complementarity between the target and targeting sequence is sufficient to form a stable duplex. The region of complementarity of the antisense oligomers with the target RNA sequence may be as short as 8-11 bases, but is preferably 12-15 bases or more, *e.g.* 12-20 bases, or 12-25 bases. An antisense oligomer of about 14-15 bases is generally long enough to have a unique complementary sequence in the viral genome. In addition, a minimum length of complementary bases may be required to achieve the requisite binding T_m , as discussed below.

Oligomers as long as 40 bases may be suitable, where at least the minimum number of bases, *e.g.*, 8-11, preferably 12-15 bases, are complementary to the target sequence. In general, however, facilitated or active uptake in cells is optimized at oligomer lengths less than about 30, preferably less than 25, and more preferably 20 or fewer bases. For PMO

oligomers, described further below, an optimum balance of binding stability and uptake generally occurs at lengths of 18-25 bases.

The oligomer may be 100% complementary to the viral nucleic acid target sequence, or it may include mismatches, *e.g.*, to accommodate variants, as long as a
5 heteroduplex formed between the oligomer and viral nucleic acid target sequence is sufficiently stable to withstand the action of cellular nucleases and other modes of degradation which may occur *in vivo*. Oligomer backbones which are less susceptible to cleavage by nucleases are discussed below. Mismatches, if present, are less destabilizing toward the end regions of the hybrid duplex than in the middle. The number of
10 mismatches allowed will depend on the length of the oligomer, the percentage of G:C base pairs in the duplex, and the position of the mismatch(es) in the duplex, according to well understood principles of duplex stability. Although such an antisense oligomer is not necessarily 100% complementary to the viral nucleic acid target sequence, it is effective to stably and specifically bind to the target sequence, such that a biological activity of the
15 nucleic acid target, *e.g.*, expression of viral protein(s), is modulated.

The stability of the duplex formed between the oligomer and the target sequence is a function of the binding T_m and the susceptibility of the duplex to cellular enzymatic cleavage. The T_m of an antisense compound with respect to complementary-sequence RNA may be measured by conventional methods, such as those described by Hames *et al.*,
20 Nucleic Acid Hybridization, IRL Press, 1985, pp. 107-108 or as described in Miyada C.G. and Wallace R.B., 1987, Oligonucleotide hybridization techniques, *Methods Enzymol.* Vol. 154 pp. 94-107. Each antisense oligomer should have a binding T_m , with respect to a complementary-sequence RNA, of greater than body temperature and preferably greater than 50°C. T_m 's in the range 60-80°C or greater are preferred. According to well known
25 principles, the T_m of an oligomer compound, with respect to a complementary-based RNA hybrid, can be increased by increasing the ratio of C:G paired bases in the duplex, and/or by increasing the length (in base pairs) of the heteroduplex. At the same time, for purposes of optimizing cellular uptake, it may be advantageous to limit the size of the oligomer. For this reason, compounds that show high T_m (50°C or greater) at a length of 20 bases or less
30 are generally preferred over those requiring greater than 20 bases for high T_m values.

Table 4 below shows exemplary targeting sequences, in a 5'-to-3' orientation, that target the Ebola Zaire virus (GenBank Acc. No. AF086833) according to the guidelines described above. The sequences listed provide a collection of targeting sequences from

which additional targeting sequences may be selected, according to the general class rules discussed above. SEQ ID NOs:16-43 are antisense to the positive strand (mRNA) of the virus whereas SEQ ID NO:15 is antisense to the minus strand viral RNA.

5 **TABLE 4. Exemplary Antisense Oligomer Sequences Targeting Ebola Zaire**

Name	Target GenBank No. AF086833	Sequence 5'-3'	SEQ ID NO
Str. Inh. 1	1-22 (-) strand	CGGACACACAAAAAGAAAGAAG	15
L-AUG	11588-11567	GTAGCCATTTAATATCAAGAGG	16
L'-AUG	11581-11600	TGGGTATGTTGTGTAGCCAT	17
L-29-AUG	11552-11573	CAAGAGGAAGAATTTCAACTGC	18
L+4-AUG	11584-11604	GTATTGGGTATGTTGTGTAGC	19
L+11-AUG	11591-11611	CGTCTGGGTATGGGTATGTT	20
VP35-AUG	3136-3115	GTTGTCATCTTGTAGACCAGC	21
VP35'-AUG	3133-3152	CCTGCCCTTTGTTCTAGTTG	22
VP35-22-AUG	3032-3053	GATGAAGTTTTAATCTTCATC	23
VP35-19-AUG	3115-3133	GTCATCTTGTAGACCAGC	24
VP35-16-AUG	3118-3133	GTCATCTTGTAGACC	25
VP35+2-AUG	3131-3152	CCTGCCCTTTGTTCTAGTTGTC	26
NP-AUG	464-483	GGACGAGAATCCATACTCGG	27
NP+4-AUG	473-495	CAGATTTTCTGAGGACGAGAATC	28
NP+11-AUG	480-499	CATCCAGATTTTCTGAGGAC	29
NP+18-AUG	487-507	CTCGGCGCCATCCAGATTTTC	30
NP-19-AUG	451-472	CATACTCGGAATTTTGTGATTC	31
VP40-AUG	4481-4498	GGCAATATAACCCGCCTC	32
VP30-AUG	8494-8512	CCATTTAAAAGTTGTCTCC	33
VP24-AUG	10331-10349	GCCATGGTTTTTTCTCAGG	34
VP24-28-AUG	10317-10336	CTCAGGTCTTGCTTGGTGTC	35
VP24+4-AUG	10348-10369	TGTATCGTCCCGTAGCTTTAGC	36
VP24+10-AUG	10354-10372	GATTGTATCGTCCCGTAGC	37
VP24+19-AUG	10361-10382	GGCGATATTAGATTGTATCGTC	38
VP24-5'trm	10261-10280	TTCAACCTTGAAACCTTGCG	39
VP24(8+)-AUG	10331-10349	GCCA+TGG+T+T+T+T+T+TC+TCAGG	40
VP24-5'trm(6+)	10261-10280	+T+TCAACC+T+TGAAACC+T+TGCG	41
panVP35	3032-3053	GATGAAGTTTTAATCTTCATC	42
Scr3	4390-4407 8288-8305	TTTTTCTTAATCTTCATC	43

In Table 4, above, SEQ ID NOs:40 and 41 are shown with cationic linkages (+) wherein X=(1-piperazino) as shown in Fig. 1B and Fig. 2H. Also in Table 4, above, SEQ ID NOs: 42 and 43 correspond to antisense oligomers that target the 5' terminal nucleotide region of the Ebola virus VP35 mRNA (SEQ ID NO:42) and the 5' terminal nucleotide region of both the Ebola virus VP40 and VP30 mRNAs (SEQ ID NO:43).

Table 5 below shows exemplary targeting sequences, in a 5'-to-3' orientation, that target the Marburg virus (GenBank Acc. No. Z29337) according to the guidelines described above. The sequences listed provide a collection of targeting sequences from which additional targeting sequences may be selected, according to the general class rules discussed above. SEQ ID NOs:45-58 are antisense to the positive strand (mRNA) of the virus whereas SEQ ID NO:44 is antisense to the minus strand viral RNA.

TABLE 5. Exemplary Antisense Oligomer Sequences Targeting Marburg Virus

Name	Target GenBank No. Z29337	Sequence 5'-3'	SEQ ID NO
(-)3'term	1-21 (-)	GACACACAAAAACAAGAGATG	44
L-AUG	11467-11485	GCTGCATATTGAAGAAAGG	45
L+7-AUG	11485-11506	CATCAGGATATTGAGTTGGATG	46
VP35-AUG	2932-2952	GCCCCACATTGTGAAAATTAT	47
VP35+7-AUG	2950-2971	CTTGTTGCATATATGATGAGTC	48
NP-AUG	94-112	GTAATCCATCTTTTCAAG	49
NP-6-AUG	97-120	CAAGCTATGTAAATCCATCTTTTC	50
NP+4-AUG	106-124	CCTAACAGCTATGTAAATC	51
NP-5'SL	68-88	TAACAGACTGACAAGTCTCAA	52
NP-5'UTR	44-64	CAATGTTAATATTCTTCTTTA	53
NP-5'UTRb	36-56	ATATTCTTCTTTATTTATATGT	54
VP30-AUG	8852-8873	GTTGCATTTTAAATCTTGAATC	55
VP35-5'UTR	2848-2867	CCTTTAATATTCTTCGATTT	56
VP24+5-AUG	10209-10231	GTTGTAACGCGTTGATAATTCTG	57
NP-stem loop	58-77	CAAGTCTCAATGTCAATGTT	58

III. Antisense Oligonucleotide analog compounds

A. Properties

As detailed above, the antisense oligonucleotide analog compound (the term "antisense" indicates that the compound is targeted against either the virus' positive-sense strand RNA or negative-sense or minus-strand) has a base sequence target region that

includes one or more of the following: 1) 125 bases surrounding the AUG start codons of viral mRNA and/or; 2) 30 bases at the 3' terminus of the minus strand viral RNA and/or; 3) 25 bases at the 5' terminus of viral mRNA transcripts. In addition, the oligomer is able to effectively target infecting viruses, when administered to a host cell, *e.g.* in an infected mammalian subject. This requirement is met when the oligomer compound (a) has the ability to be actively taken up by mammalian cells, and (b) once taken up, form a duplex with the target RNA with a T_m greater than about 45°C.

As will be described below, the ability to be taken up by cells requires that the oligomer backbone be substantially uncharged, and, preferably, that the oligomer structure is recognized as a substrate for active or facilitated transport across the cell membrane. The ability of the oligomer to form a stable duplex with the target RNA will also depend on the oligomer backbone, as well as factors noted above, the length and degree of complementarity of the antisense oligomer with respect to the target, the ratio of G:C to A:T base matches, and the positions of any mismatched bases. The ability of the antisense oligomer to resist cellular nucleases promotes survival and ultimate delivery of the agent to the cell cytoplasm.

Below are disclosed methods for testing any given, substantially uncharged backbone for its ability to meet these requirements.

B. Active or facilitated uptake by cells

The antisense compound may be taken up by host cells by facilitated or active transport across the host cell membrane if administered in free (non-complexed) form, or by an *endocytotic mechanism if administered in complexed form.*

In the case where the agent is administered in free form, the antisense compound should be substantially uncharged, meaning that a majority of its intersubunit linkages are uncharged at physiological pH. Experiments carried out in support of the invention indicate that a small number of net charges, *e.g.*, 1-2 for a 15- to 20-mer oligomer, can in fact enhance cellular uptake of certain oligomers with substantially uncharged backbones. The charges may be carried on the oligomer itself, *e.g.*, in the backbone linkages, or may be terminal charged-group appendages. Preferably, the number of charged linkages is no more than one charged linkage per four uncharged linkages. More preferably, the number is no more than one charged linkage per ten, or no more than one per twenty, uncharged linkages. In one embodiment, the oligomer is fully uncharged.

An oligomer may also contain both negatively and positively charged backbone linkages, as long as opposing charges are present in approximately equal number. Preferably, the oligomer does not include runs of more than 3-5 consecutive subunits of either charge. For example, the oligomer may have a given number of anionic linkages, *e.g.* phosphorothioate or N3'→P5' phosphoramidate linkages, or cationic linkages, such as N,N-diethylenediamine phosphoramidates (Dagle, Littig *et al.* 2000) or 1-piperazino phosphoramidates (Fig. 2H). The net charge is preferably neutral or at most 1-8 net charges per oligomer.

In addition to being substantially or fully uncharged, the antisense agent is preferably a substrate for a membrane transporter system (*i.e.* a membrane protein or proteins) capable of facilitating transport or actively transporting the oligomer across the cell membrane. This feature may be determined by one of a number of tests for oligomer interaction or cell uptake, as follows.

A first test assesses binding at cell surface receptors, by examining the ability of an oligomer compound to displace or be displaced by a selected charged oligomer, *e.g.*, a phosphorothioate oligomer, on a cell surface. The cells are incubated with a given quantity of test oligomer, which is typically fluorescently labeled, at a final oligomer concentration of between about 10-300 nM. Shortly thereafter, *e.g.*, 10-30 minutes (before significant internalization of the test oligomer can occur), the displacing compound is added, in incrementally increasing concentrations. If the test compound is able to bind to a cell surface receptor, the displacing compound will be observed to displace the test compound. If the displacing compound is shown to produce 50% displacement at a concentration of 10X the test compound concentration or less, the test compound is considered to bind at the same recognition site for the cell transport system as the displacing compound.

A second test measures cell transport, by examining the ability of the test compound to transport a labeled reporter, *e.g.*, a fluorescence reporter, into cells. The cells are incubated in the presence of labeled test compound, added at a final concentration between about 10-300 nM. After incubation for 30-120 minutes, the cells are examined, *e.g.*, by microscopy, for intracellular label. The presence of significant intracellular label is evidence that the test compound is transported by facilitated or active transport.

The antisense compound may also be administered in complexed form, where the complexing agent is typically a polymer, *e.g.*, a cationic lipid, polypeptide, or non-biological cationic polymer, having an opposite charge to any net charge on the antisense

compound. Methods of forming complexes, including bilayer complexes, between anionic oligonucleotides and cationic lipid or other polymer components, are well known. For example, the liposomal composition Lipofectin® (Felgner, Gadek *et al.* 1987), containing the cationic lipid DOTMA (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride) and the neutral phospholipid DOPE (dioleoyl phosphatidyl ethanolamine), is widely used. After administration, the complex is taken up by cells through an endocytotic mechanism, typically involving particle encapsulation in endosomal bodies.

The antisense compound may also be administered in conjugated form with an arginine-rich peptide linked covalently to the 5' or 3' end of the antisense oligomer. The peptide is typically 8-16 amino acids and consists of a mixture of arginine, and other amino acids including phenylalanine and cysteine. The use of arginine-rich peptide-PMO conjugates can be used to enhance cellular uptake of the antisense oligomer (See, *e.g.* (Moulton, Nelson *et al.* 2004; Nelson, Stein *et al.* 2005). Exemplary arginine-rich peptides are listed as SEQ ID NOs:61-66 in the Sequence Listing.

In some instances, liposomes may be employed to facilitate uptake of the antisense oligonucleotide into cells. (See, *e.g.*, Williams, S.A., *Leukemia* 10(12):1980-1989, 1996; Lappalainen *et al.*, *Antiviral Res.* 23:119, 1994; Uhlmann *et al.*, "Antisense oligonucleotides: A new therapeutic principle," *Chemical Reviews*, Volume 90, No. 4, pages 544-584, 1990; Gregoriadis, G., Chapter 14, *Liposomes, Drug Carriers in Biology and Medicine*, pp. 287-341, Academic Press, 1979). Hydrogels may also be used as vehicles for antisense oligomer administration, for example, as described in WO 93/01286. Alternatively, the oligonucleotides may be administered in microspheres or microparticles. (See, *e.g.*, Wu, G.Y. and Wu, C.H., *J. Biol. Chem.* 262:4429-4432, 1987). Alternatively, the use of gas-filled microbubbles complexed with the antisense oligomers can enhance delivery to target tissues, as described in US Patent No. 6,245,747.

Alternatively, and according to another aspect of the invention, the requisite properties of oligomers with any given backbone can be confirmed by a simple *in vivo* test, in which a labeled compound is administered to an animal, and a body fluid sample, taken from the animal several hours after the oligomer is administered, assayed for the presence of heteroduplex with target RNA. This method is detailed in subsection D below.

C. Substantial resistance to RNaseH

Two general mechanisms have been proposed to account for inhibition of expression by antisense oligonucleotides. (See *e.g.*, (Agrawal, Mayrand et al. 1990; Bonham, Brown et al. 1995; Boudvillain, Guerin et al. 1997). In the first, a heteroduplex formed between the oligonucleotide and the viral RNA acts as a substrate for RNaseH, leading to cleavage of the viral RNA. Oligonucleotides belonging, or proposed to belong, to this class include phosphorothioates, phosphotriesters, and phosphodiester s (unmodified "natural" oligonucleotides). Such compounds expose the viral RNA in an oligomer:RNA duplex structure to hydrolysis by RNaseH, and therefore loss of function.

A second class of oligonucleotide analogs, termed "steric blockers" or, alternatively, "RNaseH inactive" or "RNaseH resistant", have not been observed to act as a substrate for RNaseH, and are believed to act by sterically blocking target RNA nucleocytoplasmic transport, splicing or translation. This class includes methylphosphonates (Toulme, Tinevez et al. 1996), morpholino oligonucleotides, peptide nucleic acids (PNA's), certain 2'-O-allyl or 2'-O-alkyl modified oligonucleotides (Bonham, Brown et al. 1995), and N3'→P5' phosphoramidates (Ding, Grayaznov et al. 1996; Gee, Robbins et al. 1998).

A test oligomer can be assayed for its RNaseH resistance by forming an RNA:oligomer duplex with the test compound, then incubating the duplex with RNaseH under a standard assay conditions, as described in Stein *et al.* After exposure to RNaseH, the presence or absence of intact duplex can be monitored by gel electrophoresis or mass spectrometry.

D. In vivo uptake

In accordance with another aspect of the invention, there is provided a simple, rapid test for confirming that a given antisense oligomer type provides the required characteristics noted above, namely, high T_m , ability to be actively taken up by the host cells, and substantial resistance to RNaseH. This method is based on the discovery that a properly designed antisense compound will form a stable heteroduplex with the complementary portion of the viral RNA target when administered to a mammalian subject, and the heteroduplex subsequently appears in the urine (or other body fluid). Details of this method are also given in co-owned U.S. Patent applications, Serial No. 09/736,920, entitled "Non-Invasive Method for Detecting Target RNA" (Non-Invasive Method), the disclosure of which is incorporated herein by reference.

Briefly, a test oligomer containing a backbone to be evaluated, having a base sequence targeted against a known RNA, is injected into a mammalian subject. The antisense oligomer may be directed against any intracellular RNA, including a host RNA or the RNA of an infecting virus. Several hours (typically 8-72) after administration, the urine is assayed for the presence of the antisense-RNA heteroduplex. If heteroduplex is detected, the backbone is suitable for use in the antisense oligomers of the present invention.

The test oligomer may be labeled, *e.g.* by a fluorescent or a radioactive tag, to facilitate subsequent analyses, if it is appropriate for the mammalian subject. The assay can be in any suitable solid-phase or fluid format. Generally, a solid-phase assay involves first binding the heteroduplex analyte to a solid-phase support, *e.g.*, particles or a polymer or test-strip substrate, and detecting the presence/amount of heteroduplex bound. In a fluid-phase assay, the analyte sample is typically pretreated to remove interfering sample components. If the oligomer is labeled, the presence of the heteroduplex is confirmed by detecting the label tags. For non-labeled compounds, the heteroduplex may be detected by immunoassay if in solid phase format or by mass spectroscopy or other known methods if in solution or suspension format.

When the antisense oligomer is complementary to a virus-specific region of the viral genome (such as those regions of filovirus viral RNA or mRNA, as described above) the method can be used to detect the presence of a given filovirus, or reduction in the amount of virus during a treatment method.

E. Exemplary oligomer backbones

Examples of nonionic linkages that may be used in oligonucleotide analogs are shown in Figs. 2A-2G. In these figures, B represents a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, preferably selected from adenine, cytosine, guanine and uracil. Suitable backbone structures include carbonate (2A, R=O) and carbamate (2A, R=NH₂) linkages (Mertes and Coats 1969; Gait, Jones *et al.* 1974); alkyl phosphonate and phosphotriester linkages (2B, R=alkyl or -O-alkyl) (Lesnikowski, Jaworska *et al.* 1990); amide linkages (2C) (Blommers, Pieleles *et al.* 1994); sulfone and sulfonamide linkages (2D, R₁, R₂ = CH₂); and a thioformacetyl linkage (2E) (Cross, Rice *et al.* 1997). The latter is reported to have enhanced duplex and triplex stability with respect to phosphorothioate antisense

compounds (Cross, Rice *et al.* 1997). Also reported are the 3'-methylene-N-methylhydroxyamino compounds of structure 2F.

Peptide nucleic acids (PNAs) are analogs of DNA in which the backbone is structurally homomorphous with a deoxyribose backbone, consisting of N-(2-aminoethyl) glycine units to which pyrimidine or purine bases are attached. PNAs containing natural pyrimidine and purine bases hybridize to complementary oligonucleotides obeying Watson-Crick base-pairing rules, and mimic DNA in terms of base pair recognition (Egholm, Buchardt *et al.* 1993). The backbone of PNAs are formed by peptide bonds rather than phosphodiester bonds, making them well-suited for antisense applications. The backbone is uncharged, resulting in PNA/DNA or PNA/RNA duplexes which exhibit greater than normal thermal stability. PNAs are not recognized by nucleases or proteases.

A preferred oligomer structure employs morpholino-based subunits bearing base-pairing moieties, joined by uncharged linkages, as described above. Especially preferred is a substantially uncharged phosphorodiamidate-linked morpholino oligomer, such as illustrated in Figs. 1A-1D. Morpholino oligonucleotides, including antisense oligomers, are detailed, for example, in co-owned U.S. Patent Nos. 5,698,685, 5,217,866, 5,142,047, 5,034,506, 5,166,315, 5,185,444, 5,521,063, and 5,506,337, all of which are expressly incorporated by reference herein.

Important properties of the morpholino-based subunits include: the ability to be linked in a oligomeric form by stable, uncharged backbone linkages; the ability to support a nucleotide base (*e.g.* adenine, cytosine, guanine or uracil) such that the polymer formed can hybridize with a complementary-base target nucleic acid, including target RNA, with high T_m , even with oligomers as short as 10-14 bases; the ability of the oligomer to be actively transported into mammalian cells; and the ability of the oligomer:RNA heteroduplex to resist RNase degradation.

Exemplary backbone structures for antisense oligonucleotides of the invention include the β -morpholino subunit types shown in Figs. 1A-1D, each linked by an uncharged, phosphorus-containing subunit linkage. Fig. 1A shows a phosphorus-containing linkage which forms the five atom repeating-unit backbone, where the morpholino rings are linked by a 1-atom phosphoamide linkage. Fig. 1B shows a linkage which produces a 6-atom repeating-unit backbone. In this structure, the atom Y linking the 5' morpholino carbon to the phosphorus group may be sulfur, nitrogen, carbon or, preferably, oxygen. The X moiety pendant from the phosphorus may be fluorine, an alkyl

or substituted alkyl, an alkoxy or substituted alkoxy, a thioalkoxy or substituted thioalkoxy, or unsubstituted, monosubstituted, or disubstituted nitrogen, including cyclic structures, such as morpholines or piperidines. Alkyl, alkoxy and thioalkoxy preferably include 1-6 carbon atoms. The Z moieties are sulfur or oxygen, and are preferably oxygen.

5 The linkages shown in Fig. 1C and 1D are designed for 7-atom unit-length backbones. In Structure 1C, the X moiety is as in Structure 1B, and the moiety Y may be methylene, sulfur, or, preferably, oxygen. In Structure 1D, the X and Y moieties are as in Structure 1B. Particularly preferred morpholino oligonucleotides include those composed of morpholino subunit structures of the form shown in Fig. 1B, where X=NH₂ or N(CH₃)₂,
10 Y=O, and Z=O.

As noted above, the substantially uncharged oligomer may advantageously include a limited number of charged linkages, *e.g.* up to about 1 per every 5 uncharged linkages, more preferably up to about 1 per every 10 uncharged linkages. Therefore a small number of charged linkages, *e.g.* charged phosphoramidate or phosphorothioate, may also be
15 incorporated into the oligomers. A preferred cationic linkage is 1-piperazino phosphoramidate as shown in Fig. 2H.

The antisense compounds can be prepared by stepwise solid-phase synthesis, employing methods detailed in the references cited above. In some cases, it may be desirable to add additional chemical moieties to the antisense compound, *e.g.* to enhance
20 pharmacokinetics or to facilitate capture or detection of the compound. Such a moiety may be covalently attached, typically to a terminus of the oligomer, according to standard synthetic methods. For example, addition of a polyethyleneglycol moiety or other hydrophilic polymer, *e.g.*, one having 10-100 monomeric subunits, may be useful in enhancing solubility. One or more charged groups, *e.g.*, anionic charged groups such as an
25 organic acid, may enhance cell uptake. A reporter moiety, such as fluorescein or a radiolabeled group, may be attached for purposes of detection. Alternatively, the reporter label attached to the oligomer may be a ligand, such as an antigen or biotin, capable of binding a labeled antibody or streptavidin. In selecting a moiety for attachment or
30 modification of an antisense oligomer, it is generally of course desirable to select chemical compounds of groups that are biocompatible and likely to be tolerated by a subject without undesirable side effects.

IV. Inhibition of Filovirus ReplicationA. Inhibition in Vero cells:

PMO antisense compounds and the control PMO (SEQ ID NO:35) were initially evaluated for cytotoxicity when incubated with Vero cells (Fig. 5) in the absence of virus.

5 Only one PMO (0-1-63-308) was found to show dose dependent cytotoxicity in the concentration range of 5 to 25 μ M.

Viral titer data were obtained 10 days post-infection of Vero cells. All inhibitors evaluated to date reduce the viral titer, as measured by TCID₅₀, to some degree (Table 6 below) but the VP35-AUG inhibitor (SEQ ID NO:21) was the most inhibitory against
 10 Ebola virus. The inoculum was taken from cells which received the treatment after infection (15 μ M). No serum was added to media during pre-incubation with inhibitor or during infection. After the infection the inoculum was removed and replaced the medium containing 2% serum. The VP35-AUG PMO produced a 3 log reduction in viral titer relative to the no treatment control group. The L-AUG PMO (SEQ ID NO:16) did not
 15 produce reduction in viral titer. The L gene is active later in the viral life cycle and the RNA becomes highly bound by NP, VP30 and VP45 proteins so this target may be inaccessible to the L-AUG PMO used in this experiment.

TABLE 6. Viral Titer Reduction in Vero cells

20

Treatment (PMO)	TCID₅₀	TCID₅₀/ml
Control (no treatment)	-5.5	3.16 x 10 ⁶
VP35-scr (SEQ ID NO:60)	-3.2	1.47 x 10 ⁴
Dscr (SEQ ID NO:59)	-3.8	6.81 x 10 ⁴
L-AUG (SEQ ID NO:16)	-4.2	1.47 x 10 ⁵
VP35-AUG (SEQ ID NO:21)	-2.5	3.16 x 10 ³

Vero cells were pretreated with different concentrations of the PMO (namely 0.1, 0.5, 1.0, 2.5, 5.0 and 10 μ M), infected with EBOV for 1 h and the same concentration of PMO was added back afterwards. The 1 μ M concentration of VP35-AUG (SEQ ID NO:21)
 25 inhibitor reduced the cytopathic effect (CPE) significantly compared to 0.5 μ M concentration. The reduction in CPE has been repeatedly observed in culture and an example of these studies is seen in Figs. 6A-6C for non-infected (Fig. 6A), infected, no treatment (Fig. 6B), and infected and treated (Fig. 6C).

B. Treatment in infected mice

These observations involved C57BL mice treated intraperitoneally (IP) with PMO at -24 and -4 hours prior to viral challenge at time 0. Each treatment group is composed of 10 male mice. The Ebola Zaire infection involves 100 pfu injected IP and death is the endpoint observed between days 7 and 10 post infection. A summary of studies to date is provided in Table 7. The dose x 2 indicates the dose given at the two times prior to viral infection. The VP35-AUGcon compound refers to the VP35-AUG PMO that has been conjugated with the arginine-rich peptide R₉F₂C (SEQ ID NO:61).

TABLE 7. Summary of Treatment in Mice

Group	Dose	Survivors/challenged
Saline	na	1/10
Str. Ihn 1 (SEQ ID NO:15)	0.5 mg x2	0/10
VP35-AUG (SEQ ID NO:21)	0.5 mgx2	6/10
Saline	na	0/10
Str. Ihn 1 (SEQ ID NO:15)	1.0 mg x2	2/10
VP35-AUG (SEQ ID NO:21)	1.0 mg x2	7/10
Scramble (SEQ ID NO:60)	1.0 mg x2	1/10
VP35-AUG + Str Inh 1 (SEQ ID NOs:21 and 15)	1.0 mg x 2	6/10
VP35-AUG-P003 + VP35-AUG (SEQ ID NO:21+61 and 21)	0.5 mg + 1.0 mg	9/10
VP35-AUG-P003 (SEQ ID NO:21+61)	0.5 mg x2	9/10

Mice that survived the viral challenge described in TABLE 7 were rechallenged with virus to determine the immunological consequence of treatment. The results of the first studies are summarized in TABLE 8.

TABLE 8. Rechallenge Studies in Mice

Group	Earlier dose	Survivors/challenged
Saline	na	0/10
Str. Ihn 1, 0-1-63-412	0.5 mg x2	1/2
VP35, 0-1-63-413	0.5 mg x2	6/6
VP35, 0-1-63-413	1.0 mg x2	7/7

All survivors from earlier Ebola challenge studies were evaluated in re-challenge studies 2 to 4 weeks after the initial viral exposure. The MOI for the re-challenge was identical to the initial challenge. All of the re-challenged survivors from therapeutic treatment with the PMO targeting VP35-AUG survived the re-challenge. These
 5 observations suggest viral replication was initiated in the viral challenge leading to a robust immune response, essentially a perfect vaccination. In accordance with another aspect, the invention includes a method of vaccinating a mammalian subject against Ebola virus by (i) pretreating the subject with antisense to Ebola virus, *e.g.*, administering a VP35 antisense or compound combination at one or two times prior to Ebola virus challenge, and (ii)
 10 challenging the individual with the virus, preferably in an attenuated form incapable of producing serious infection.

Similar treatment methods were aimed at determining the optimal length for anti-Ebola PMO antisense, employing various length VP35 antisense PMO. As seen from the data below (Table 9) and the plot in Fig. 7, the 16-mer is less effective than the 19-mer
 15 which is less effective than the 22-mer which is in the same order as the predicted T_m.

TABLE 9. Studies to Identify Optimal VP35-AUG Targeting Sequence

Group	AVI Number	Survivors/challenged*
Saline	NA	1/10
VP35scr	SEQ ID NO:60	1/10
VP35-16	SEQ ID NO:25	3/10
VP35-19	SEQ ID NO:24	5/10
VP35-22	SEQ ID NO:23	9/10
VP35'-AUG	SEQ ID NO:22	10/10; 9/10

*Observations as of day 9 post challenge

20

Antisense compounds against six of the seven different genes expressed by Ebola were evaluated in the mouse model in a head-to-head experiment. (The GP gene was not included). As seen in Table 10, below, the most effective PMOs target VP24 and VP35 with L, VP40 and VP30 demonstrating less robust but significant activity in reducing
 25 mortality.. The mice treated with VP40 died later than controls and those that survived appeared to be less active. These data indicate differences in the efficacy for the different gene targets. As single antisense compounds, the antisense against VP35 and VP24 are preferred therapeutic agents.

TABLE 10. Comparison of Ebola Gene Targets

Target	SEQ ID NO	Survivors/challenged*
NP-AUG	27	2/10
VP40-AUG	32	5/10
VP30-AUG	33	5/10
VP24-AUG	34	10/10; 5/10
L'-AUG	17	6/10; 2/10
VP35-22	23	9/10
Scramble	60	0/10; 0/10
PBS	NA	1/10; 0/10

* Dose 0.5 mg IP at -24 and -4 hours to challenge, second survival numbers are from repeat experiment with fresh virus preparation.

5

In one embodiment, the antisense compound is administered in a composition (or separately) in combination with one or more other antisense compounds. One preferred combination is VP35-AUG (SEQ ID NO:21) plus VP24-AUG (SEQ ID NO:34); another is VP35-AUG, VP24-AUG and L'-AUG (SEQ ID NOs:21, 34 and 16, respectively). As seen in Table 11 below, and as plotted in Fig. 8, the dose response curves for a combination of the 3 compounds (VP35-AUG, VP24-AUG and L'-AUG, each given IP at 0.5 mg/dose) is not different from 5 different compounds (VP35-AUG, VP24-AUG, L'-AUG, VP24-AUG and VP40-AUG). The dose of 0.5 mg/mouse provides 100 percent survival from either combination. Further, these data indicate the EC₅₀ for combination therapy is between 10 and 30 μg/mouse and that the EC₉₀ is approximately 50 μg/mouse.

15

TABLE 11. Combination Treatment for Ebola

Group	SEQ ID NOs	Survivors/Challenged
PBS	NA	0/10
NP-AUG, VP40-AUG, VP30-AUG, VP24-AUG, and L'-AUG	27, 32-34 and 17	9/10
NP-AUG, VP40-AUG, VP30-AUG, VP24-AUG, L'-AUG and VP35-AUG	27, 32-34, 17 and 21	10/10
VP35-AUG, VP24-AUG and L'-AUG	21, 34 and 17	10/10
VP35-AUG, VP24-AUG, L'-AUG, VP40-AUG and VP30-AUG	21, 34, 17, 32 and 33	10/10

* Each agent in the combination administered 0.5 mg via IP route.

The success with 100 percent survival from a single IP injection 24 hours after Ebola infection (via IP route) indicates the antisense mechanism can suppress virus after viral replication has distributed throughout the body and that these agents can be used as therapy for infected individuals (Table 12 and Figure 9). The comparison of dose-response in the -24 and -4 hour regimen between VP35-AUG only and the 3 agent combination is clear evidence of synergy. The combination could be more effective at 0.1x the dose than a single agent.

TABLE 12. Comparison of Dose Regimens

Treatment	Dose (mg)	-24 and -4 hours	-4 hours only	+24 hours
VP35-AUG (SEQ ID NO:21)	0.5	9/10		
	0.05	4/10		
VP35-AUG, VP24-AUG and L'-AUG (SEQ ID NOs:21, 34 & 17)	0.5	10/10	10/10	10/10
	0.05	10/10	4/10	5/10
	0.005		0/10	4/10

V. Treatment Method

The antisense compounds detailed above are useful in inhibiting Ebola viral infection in a mammalian subject, including human subjects. Accordingly, the method of the invention comprises, in one embodiment, contacting a cell infected with the virus with an antisense agent effective to inhibit the replication of the virus. In one embodiment, the antisense agent is administered to a mammalian subject, *e.g.*, human or domestic animal, infected with a given virus, in a suitable pharmaceutical carrier. It is contemplated that the antisense oligonucleotide arrests the growth of the RNA virus in the host. The RNA virus may be decreased in number or eliminated with little or no detrimental effect on the normal growth or development of the host.

A. Identification of the Infective Agent

The specific Ebola strain causing the infection can be determined by methods known in the art, *e.g.* serological or cultural methods, or by methods employing the antisense oligomers of the present invention.

Serological identification employs a viral sample or culture isolated from a biological specimen, *e.g.*, stool, urine, cerebrospinal fluid, blood, *etc.*, of the subject. Immunoassay for the detection of virus is generally carried out by methods routinely

employed by those of skill in the art, *e.g.*, ELISA or Western blot. In addition, monoclonal antibodies specific to particular viral strains or species are often commercially available.

Another method for identifying the Ebola viral strain employs one or more antisense oligomers targeting specific viral strains. In this method, (a) the oligomer(s) are administered to the subject; (b) at a selected time after said administering, a body fluid sample is obtained from the subject; and (c) the sample is assayed for the presence of a nuclease-resistant heteroduplex comprising the antisense oligomer and a complementary portion of the viral genome. Steps (a) – (c) are carried for at least one such oligomer, or as many as is necessary to identify the virus or family of viruses. Oligomers can be administered and assayed sequentially or, more conveniently, concurrently. The viral strain is identified based on the presence (or absence) of a heteroduplex comprising the antisense oligomer and a complementary portion of the viral genome of the given known virus or family of viruses.

Preferably, a first group of oligomers, targeting broad families, is utilized first, followed by selected oligomers complementary to specific genera and/or species and/or strains within the broad family/genus thereby identified. This second group of oligomers includes targeting sequences directed to specific genera and/or species and/or strains within a broad family/genus. Several different second oligomer collections, *i.e.* one for each broad virus family/genus tested in the first stage, are generally provided. Sequences are selected which are (i) specific for the individual genus/species/strains being tested and (ii) not found in humans.

B. Administration of the Antisense Oligomer

Effective delivery of the antisense oligomer to the target nucleic acid is an important aspect of treatment. In accordance with the invention, routes of antisense oligomer delivery include, but are not limited to, various systemic routes, including oral and parenteral routes, *e.g.*, intravenous, subcutaneous, intraperitoneal, and intramuscular, as well as inhalation, transdermal and topical delivery. The appropriate route may be determined by one of skill in the art, as appropriate to the condition of the subject under treatment. For example, an appropriate route for delivery of a antisense oligomer in the treatment of a viral infection of the skin is topical delivery, while delivery of a antisense oligomer for the treatment of a viral respiratory infection is by inhalation. The oligomer may also be delivered directly to the site of viral infection, or to the bloodstream.

The antisense oligomer may be administered in any convenient vehicle which is physiologically acceptable. Such a composition may include any of a variety of standard pharmaceutically accepted carriers employed by those of ordinary skill in the art. Examples include, but are not limited to, saline, phosphate buffered saline (PBS), water, aqueous ethanol, emulsions, such as oil/water emulsions or triglyceride emulsions, tablets and capsules. The choice of suitable physiologically acceptable carrier will vary dependent upon the chosen mode of administration.

In some instances, liposomes may be employed to facilitate uptake of the antisense oligonucleotide into cells. (See, *e.g.*, Williams, S.A., *Leukemia* 10(12):1980-1989, 1996; Lappalainen *et al.*, *Antiviral Res.* 23:119, 1994; Uhlmann *et al.*, "Antisense oligonucleotides: A new therapeutic principle," *Chemical Reviews*, Volume 90, No. 4, pages 544-584, 1990; Gregoriadis, G., Chapter 14, *Liposomes, Drug Carriers in Biology and Medicine*, pp. 287-341, Academic Press, 1979). Hydrogels may also be used as vehicles for antisense oligomer administration, for example, as described in WO 93/01286. Alternatively, the oligonucleotides may be administered in microspheres or microparticles. (See, *e.g.*, Wu, G.Y. and Wu, C.H., *J. Biol. Chem.* 262:4429-4432, 1987). Alternatively, the use of gas-filled microbubbles complexed with the antisense oligomers can enhance delivery to target tissues, as described in US Patent No. 6,245,747.

Sustained release compositions may also be used. These may include semipermeable polymeric matrices in the form of shaped articles such as films or microcapsules.

The antisense compound is generally administered in an amount and manner effective to result in a peak blood concentration of at least 200-400 nM antisense oligomer. Typically, one or more doses of antisense oligomer are administered, generally at regular intervals, for a period of about one to two weeks. Preferred doses for oral administration are from about 5-1000 mg oligomer or oligomer cocktail per 70 kg individual. In some cases, doses of greater than 500 mg oligomer/patient may be necessary. For i.v., i.p or s.q. administration, preferred doses are from about 100-1000 mg oligomer or oligomer cocktail per 70 kg body weight. The antisense oligomer may be administered at regular intervals for a short time period, *e.g.*, daily for two weeks or less. However, in some cases the oligomer is administered intermittently over a longer period of time. Administration may be followed by, or concurrent with, administration of an antibiotic or other therapeutic treatment. The treatment regimen may be adjusted (dose, frequency, route, *etc.*) as

indicated, based on the results of immunoassays, other biochemical tests and physiological examination of the subject under treatment.

Examples

5 Materials and Methods:

Synthesis of PMOs. PMOs were designed with sequence homology near or overlapping the AUG start site of Ebola virus VP35 (VP35'-AUG, SEQ ID NO:22), VP24 (VP24-AUG, SEQ ID NO:36), and L (L'-AUG, SEQ ID NO:17). Unrelated, scrambled PMOs (SEQ ID NOs:59 and 60) were used as a control in all experiments. The PMOs
10 were synthesized by AVI Biopharma, Inc. (Corvallis, OR), as previously described (Summerton and Weller 1997).

In vitro translation assay. The protein coding sequence for firefly luciferase, without the initiator-Met codon ATG, was subcloned into the multiple cloning site of plasmid pCiNeo (Promega). Subsequently, complementary oligonucleotides for Ebola
15 virus VP35 (-98 to +39 bases 3020 to 3157), Ebola virus VP24 (-84 to +43 or bases 10261 to 10390), Ebola virus L (-80 to +49 or bases 11501 to 11632) were duplexed and subcloned into Nhe I and Sal I sites. RNA was generated from the T7 promoter with T7 Mega script (Ambion, Inc., Austin, TX). The *in vitro* translations were carried out by mixing different concentrations of PMO with 6 nM RNA. A sigmoidal curve to determine
20 the EC₅₀ values was generated with the observed luciferase light emission (n=3 per PMO concentration) and the PMO concentration.

Ebola virus infection of PMO-treated animals. C57Bl/6 mice, aged 8-10 weeks of both sexes, were obtained from National Cancer Institute, Frederick Cancer Research and Development Center (Frederick, MD). Mice were housed in microisolator cages and
25 provided autoclaved water and chow *ad libitum*. Mice were challenged by intraperitoneal injection with ~1000 pfu of mouse-adapted Ebola virus diluted in phosphate buffered saline (PBS) (Bray, Davis et al. 1998). Mice were treated with a combination of 1 mg, 0.1, or 0.01 mg of each of the VP24-AUG, L'-AUG and VP35'-AUG PMOs (SEQ ID NOs:34, 17 and 22, respectively) or the scramble control PMO (SEQ ID NO:60) either split
30 between two equivalent doses at 24 and 4 hours prior to Ebola virus challenge or a single dose 24 hours after challenge. C57Bl/6 mice were challenged intraperitoneally with 1000 plaque-forming units of mouse-adapted Ebola virus (Bray, Davis et al. 1998). Hartley guinea pigs were treated intraperitoneally with 10 mg of each of the VP24-AUG, VP35'-

AUG, and L'-AUG PMOs 24 hours before or 24 or 96 hours after subcutaneous challenge with 1000 pfu of guinea-pig adapted Ebola virus (Connolly, Steele et al. 1999). Female rhesus macaques of 3-4 kg in weight were challenged with ~1000 pfu of Ebola virus ('95 strain) (Jahrling, Geisbert et al. 1999) by intramuscular injection following PMO treatment.

5 The monkeys were treated from days -2 through day 9 via a combination of parenteral routes as shown in Figure 10. The dose of the VP24-AUG PMO was 12.5-25 mg at each injection and the dose of the VP35'-AUG and L'-AUG PMOs ranged from 12.5-100 mg per injection.

10

Example 1

Antiviral efficacy of Ebola virus-specific PMOs in rodents

To determine the *in vivo* efficacy of the Ebola virus-specific PMOs, the survival of mice treated with 500 µg doses of the individual PMOs (VP24-AUG, L'-AUG and VP35'-AUG, SEQ ID NOs:34, 17 and 22, respectively) at 24 and 4 hours before challenge with 15 1000 plaque-forming units (pfu) of mouse-adapted Ebola virus was determined. The VP35'-AUG, VP24-AUG and L'-AUG PMOs exhibited a wide range of efficacy against lethal EBOV infection and the VP35'-specific PMO provided nearly complete protection (Figure 11A). Next, we performed a dose response experiment with the VP35 PMO and found that reducing the dose of the PMO from 1,000 to 100 µg reduced the efficacy 20 substantially (Figure 11B). Hence, to further enhance efficacy, we decided to use a combination of all three PMOs. This combination of PMOs administered 24 and 4 h before lethal Ebola virus challenge resulted in robust protection and showed substantial enhancement in protection afforded by the VP35 PMO alone, especially at lower doses (Figure 11B). To determine the efficacy of the combination of PMOs in a post-challenge 25 treatment regimen, mice were injected with 1,000 pfu of Ebola virus and were treated the next day with the PMOs (Figure 11C). Mice that were given a single dose of 1,000 µg 24 h after the lethal challenge and survival was scored for 14 days. Again, Ebola virus-infected mice were fully protected and lower doses showed substantial protection as compared to the control PMO. To determine the effectiveness of the PMO treatment in Ebola virus- 30 infected guinea pigs, the combination of PMOs was administered 24 hours before or 24 or 96 hours after EBOV infection. Survival was greatly increased in guinea pigs receiving the PMOs either 24 or 96 hours after infection, as compared to untreated or pretreated guinea pigs as shown in Figure 12.

Examination of tissues shortly following infection showed that treatment of mice with the combination of Ebola virus-specific PMO slowed viral spread compared to mice treated with the scrambled PMO. Three days after the infection, multiple foci of infected cells were easily observed in the spleens of the mice treated with the scrambled PMO (Figure 13D). In contrast, very few EBOV-infected cells could be found in the spleens of the anti-EBOV PMO-treated mice (Figure 13E). Six days after viral inoculation, the infection was fulminant in the spleens of all animals (data not shown) and had spread to the livers of both mice treated with scrambled and combination PMOs (Figures 13F and 13G). However, the extent of the infection was limited in the combination PMO-treated mice, and, unlike the scrambled PMO-treated mice, EBOV antigen was not detectable within their hepatocytes, (Figures 13F and 13G). The observed pattern of antigen staining within the tissues was corroborated by the viral titers as shown in Figure 14.

To determine whether mice treated with the PMO therapeutics generated immune responses to Ebola virus, they were tested for Ebola virus-specific cell-mediated and humoral immune responses. Four weeks after infection, the mice demonstrated both CD4+ and CD8+ T cell responses to multiple Ebola virus peptides, including NP and VP35 as shown in Figure 15A. They also generated strong serum Ebola virus-specific antibody responses that were similar to the post-challenge antibody responses of mice protected by a therapeutic Ebola virus-like particle vaccine as shown in Figure 15B (Warfield, Perkins et al. 2004). To study if the generated immune responses were protective, PMO-treated mice were rechallenged with another dose of 1,000 pfu of Ebola virus four weeks after surviving the initial challenge and these mice were completely protected from a second lethal Ebola virus infection as shown in Figure 15C.

25

Example 2

Antiviral efficacy of Ebola virus-specific PMOs in non-human primates

Based on the encouraging results both *in vitro* and in rodents, a trial in nonhuman primates was performed. Four rhesus monkeys were treated with PMO from two days prior to Ebola virus infection through day 9 of the infection. The naïve control monkey in this experiment received no treatment and succumbed to Ebola virus infection on day 10 as shown in Figure 16A. Of 12 rhesus monkeys that have been infected in the inventors' laboratory with the same seed stock of virus, all died of Ebola virus between days 7 and 10 as shown in Figure 16A. One of the PMO-treated monkeys succumbed to the infection on day 10. A second PMO-treated monkey cleared the EBOV infection from its circulation

between days 9 and 14, but was unable to recover from disease and died on day 16 as shown in Figures 16A and 16B. The two surviving monkeys had no symptoms of disease beyond mild depression until day 35, at which time they were euthanized. Incorporating historical controls, there were significant differences in survival curves between groups (p=0.0032). The mean survival time for the treatment group was 14.3 days with a standard error of 2.1 days. The mean survival time for the control group was 8.3 days with a standard error of 0.2 days. The overall survival rate demonstrated a significant *p* value of 0.0392, when compared to historical data.

There were early clinical signs or laboratory values that correlated with survival. The laboratory tests that most closely predicted survival were viral titers, platelet counts, and liver-associated enzymes in the blood. The monkeys that did not survive infection had detectable virus by day 5, in stark contrast to the PMO-treated monkeys that survived, which had little to no viremia on day 5 (Figure 16B). As expected in a hemorrhagic disease, both the PMO-treated and naïve monkeys exhibited thrombocytopenia. However, the PMO-treated monkeys that survived did not have platelet counts far below 100,000 at any time, and their platelet counts began to recover coincident with viral clearance (Figure 16C). Similarly, all the monkeys experienced increases in their liver-associated enzyme levels, including alkaline phosphatase. However, the levels in the surviving monkeys did not climb as high as those that succumbed to the infection, and they returned to normal levels within the month after the EBOV infection (Figure 16D). No correlation was found between survival and multiple other hematological values, body temperature, serum cytokines, or fibrin degradation products. Since the surviving PMO-treated monkeys had low to undetectable viremias following infection, we assessed the immune responses of the surviving monkeys. By 28 days after Ebola virus challenge, the surviving rhesus monkeys had high levels of both anti-EBOV antibodies and T cell responses, similar to the PMO-protected mice.

Example 3

Increased antisense of activity using PMO with cationic linkages

Two PMOs were synthesized using cationic linkages for a subset of the oligomer linkages as shown in Sequence Listing for SEQ ID NOs:40 and 41. These oligomers incorporated the cationic linkage (1-piperazino phosphoramidate) shown in Fig. 2H at the positions indicated with a "+". These two PMOs target the EBOV VP24 mRNA. A cell free translation assay was performed using the VP24:luciferase mRNA as the input RNA.

PMO with and without cationic linkages were compared for their ability to inhibit luciferase expression and the results are shown in Fig. 16. Compared to the uncharged PMO with the same base sequence, the PMOs with between 6 and 8 cationic linkages demonstrated between 10 and 100-fold increased antisense activity in this assay.

Based on the experiments performed in support of the invention as described above in the Examples, efficacious anti-filovirus PMOs have been identified. The antiviral PMOs demonstrate favorable anti-Ebola viral activity both *in vitro* and *in vivo* in both rodents and non-human primates. Together, the compounds and methods of the present invention provide a highly efficacious therapeutic treatment regimen for lethal Ebola virus infections. PMOs have already been tested in clinical trials and have appropriate pharmacokinetic and safety profiles for use in humans (Arora and Iversen 2001). The results presented here have far-reaching implications for the treatment of highly lethal Ebola virus hemorrhagic fever, as well as diseases caused by other filovirus biothreats including Marburg virus.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

Sequence Listing Table

AVI No.	Name	Target Sequences (5'-3')	SEQ ID NO
NA	VP35-AUG	AAUGAUGAAGAUUAAAACCUUCAUCAUCCU ACGUCAAUUGAAUUCUCUAGCACUCGAAGCU UAUUGUCUCAAUGUAAAAGAAAAGCUGGUC UAA CAAGAUGACAACUAGAACAAAGGGCAGG G	1
NA	VP24-AUG	CGUCCAACAAUCGAGCGCAAGGUUJUCAAGGU UGA ACUGAGAGUGUCUAGACAACAAAUAUUG AUA CUCCAGACACCAAGCAAGACCUGAGAAAA AAC CAUGGCUAAAGCUACGGGACGAUACA	2
NA	VP30-AUG	AGA UCUGCGAACCGGUAGAGUUUAGUUGCAAC CUA ACACACAUAAGCAUUGGUCAAAAAGUCA AUA GAAAUUUAAACAGUGAGUGGAGACAACUJ UUA AAUGGAAGCUUCAUAUGAGAGAGGAC	3
NA	VP40-AUG	AAA CCAAAGUGAUGAAGAUUAAGAAAAACCU ACCUCGGCUGAGAGAGUGUUUUUCAUUAACC UUC AUCUUGUAAACGUUGAGCAAAAUUGUUA AAA UAUGAGGCGGGUUAUAUUGCCUACUG	4
NA	L-AUG	GUA GAUUAAGAAAAAGCCUGAGGAAGAUUAA GAA AAACUGCUUAUUGGGUCUUCCGUGUUUJ AGA UGAAGCAGUUGAAAUCUCCUCUUGAUA UUA AAUGGCUACACAACAUACCCAUAAC	5
NA	NP-AUG	UGA ACACUUAAGGGGAUUGAAGAUUCAACAACC CUA AAGCUUGGGUAAAACAUUGGAAAUAGUJ AAA AGACAAAUUGCUCGGAAUCACAAAUUC GAG UAUGGAUUCUCGUCCUCAGAAAUCU	6
NA	Str. Ihn 1(-)	UAA AAAUUCUUCUUCUUCUUCUUCUUCUUCG	7
NA	VP35-AUG	CUA AAAAUCGAAGAAUAUUAAGGUUUUCUJ AAU AUUCAGAAAAGGUUUUUUAUUCUCUUCUJ UCU UUUUGCAAACAUAUUGAAAUAUAUUUJ CAC AAUGUGGGACUCAUCAUAUAUGCAAC	8
NA	VP24-AUG	UUC AUUCAAACCCCCAAUUUUCAUUCAUAC ACA UAAUAACCAUUUAGUAGCGUUACCUUC AAU ACAUUCUAGGUGAUUGUGAAAAGACUUC AAA CAUGGCAGAAUUAUCAACGCGUACA	9
NA	VP30-AUG	GAA GAACAUAAGUGUUCUUGUAGAAUUAU UCA UCCAAGUUGUUUGAGUAUACUCGCUUCA AUA CAACUCCCUUCAUAUUGAUUCAAGAUJ UAA AAUGCAACAACCCCGUGGAAGGAGU	10
NA	VP40-AUG	UCC CAAUCUCAGCUUGUUGAAUUAUUGUAC UUA AGUCAUUCUUUUUAAAUAUUCACACA AGG UAGUUUGGUUAUAUCUAGAACAAAUUJ UAA UAUGGCCAGUUCAGCAAUACAACA	11
NA	L-AUG	UCA UUCUCUUCGAUACACGUUAUUCUUUAGC AAA GUAAUGAAAUAAGCCUUGUCAUGUUAGAC GCC AGUUAUCCAUCUUAAGUGAAUCCUUCUJ CAA UAUGCAGCAUCCAACUCAUAUCCUG	12
NA	NP-AUG	CAC ACAAAAACAAGAGAUGAUGAUUUUGUGUA UCA UAUAAAUAAGAAGAAUAUUAACAUUGAC AUUGAGACUUGUCAGUCUGUUAUAUUCUUGA AAA GAUGGAUUUCAUAGCUUGUAGAGU	13

0176	NP-5'SL	TAACAGACTGACAAGTCTCAA	52
NA	NP-5'UTR	CAATGTTAATATTCTTCTTTA	53
0175	NP-5'UTRb	ATATTCTTCTTTATTTATATGT	54
NA	VP30-AUG	GTTGCATTTTAAATCTTGAATC	55
NA	VP35-5'UTR	CCTTTAATATTCTTCGATTT	56
0179	VP24+5-AUG	GTTGTAACGCGTTGATAATTCTG	57
NA	NP-stem loop	CAAGTCTCAATGTCAATGTT	58
Control Oligomers			
183	DSscr	AGTCTCGACTTGCTACCTCA	59
542	Scr	TGTGCTTACTGTTATACTACTC	60
Peptide Conjugates*			
NA	R9F2C	NH ₂ -RRRRRRRRRFFC-CO ₂ H	61
NA	RXR4	NH ₂ -RXXRXRXRXRXB-CO ₂ H	62
NA	P008RX8	NH ₂ -RXXRXRXRXRXRXRXB-CO ₂ H	63
NA	RX4	NH ₂ -RXXRXRXB-CO ₂ H	64
NA	RXR2	NH ₂ -RXXRXRXB-CO ₂ H	65
NA	RXR3	NH ₂ -RXXRXRXRXB-CO ₂ H	66

*"X" and "B" denote 6-aminohexanoic acid and beta-alanine, respectively.

** SEQ ID NOs:40 and 41 incorporated the cationic linkage (1-piperazino phosphoramidate) as shown in Fig. 2H, at the positions indicated with a "+".


2005302155 16 Jul 2012

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. An antiviral compound, useful in treating a Filovirus infection, comprising an oligonucleotide analog having
 - a) a nuclease-resistant backbone,
 - b) 15-40 nucleotide bases, and
 - c) a targeting sequence of at least 15 bases in length that hybridizes to a target region selected from the following:
 - i) the AUG start site region of VP35, as exemplified by antisense compounds SEQ ID NO: 21-26,
 - ii) the AUG start site region of VP24, as exemplified by antisense compound SEQ ID NO: 34,
 - iii) the region 85 to 65 base pairs upstream of the AUG start site of VP24, as exemplified by SEQ ID NO: 39,
 - iv) the AUG start site region of polymerase L, as exemplified by antisense compound SEQ ID NO: 17, and
 - v) combinations of (i), (ii), (iii), and/or (iv).
2. The compound of claim 1, wherein the oligonucleotide analog has:
 - a) the capability of being actively taken up by mammalian host cells, and
 - b) the ability to form a heteroduplex structure with the viral target region, wherein said heteroduplex structure is:
 - i) composed of the positive or negative sense strand of the virus and the oligonucleotide compound, and
 - ii) characterized by a T_m of dissociation of at least 45 °C.
3. The compound of claim 1, wherein the oligonucleotide analog is composed of morpholino subunits linked by uncharged, phosphorous-containing intersubunit linkages that join a morpholino nitrogen of one subunit to a 5' exocyclic carbon of an adjacent subunit.

2005302155 16 Jul 2012

4. The compound of claim 3, wherein the morpholinos subunits are joined by phosphorodiamidate linkages in accordance with the structure:



where $Y_1=O$, $Z=O$, P_j is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is alkyl, alkoxy, thioalkoxy, or alkyl amino.

5. The compound of claim 4 wherein $X=NR_2$, and where each R is independently hydrogen or methyl.
6. The compound of claim 1, wherein the oligonucleotide analog hybridizes to a sequence selected from the group consisting of SEQ ID NOs: 1-14.
7. The compound of claim 1, wherein the viral target region comprises one of the sequences selected from the group consisting of SEQ ID NOs: 1, 2 and 5.
8. The compound of claim 1, wherein the antisense compound has at least 12 contiguous bases from one of the sequences selected from the group consisting of SEQ ID NOs: 15-58.
9. The compound of claim 1, wherein the targeting sequence comprises

2005302155 16 Jul 2012

one of the sequences selected from the group consisting of SEQ ID Nos: 17, 22 and 34.

10. The compound of claim 1, wherein the oligonucleotide analog is conjugated to an arginine-rich polypeptide that enhances the uptake of the compound into host cells.

11. The compound of claim 10, wherein the arginine-rich polypeptide is selected from the group consisting of SEQ ID NOs: 61-66.

12. A method of treating an Ebola or Marburg virus infection in a mammalian host, by administering to the host, a therapeutically effective amount of a composition of the type described in claim 1, said method including in exemplary embodiments, administering a composition having a combination of antisense compounds targeted against different viral proteins, such as the VP35, VP24, and L polymerase proteins.

13. A method of vaccinating a mammalian subject against Ebola virus by pretreating the subject with the composition of claim 1, and exposing the subject to the Ebola virus, preferably in an attenuated form.

14. Use of the compound of any one of claims 1 to 11 in the manufacture of a medicament for treating an Ebola or Marburg virus infection.

15. The use of claim 14, wherein a combination of the compounds of any one of claims 1 to 11 is used to target against different viral proteins, such as the VP35, VP24, and L polymerase proteins.

16. Use of the compound of any one of claims 1 to 11 in the manufacture of a medicament for preventing an Ebola virus infection.

2005302155 16 Jul 2012

17. The use of claim 16, wherein the compound is formulated for pretreating a subject before exposing the subject to the Ebola virus, preferably in an attenuated form.

18. The compound of any one of claims 1 to 11, or the method of claim 12 or claim 13, or the use of any one of claims 14 to 17, substantially as hereinbefore described with reference to the figures and/or examples.




Fig. 1A




Fig. 1B




Fig. 1C




Fig. 1D




Fig. 2A




Fig. 2B




Fig. 2C




Fig. 2D




Fig. 2E




Fig. 2F




Fig. 2G




Fig. 2H




Fig. 3A

EBOLA (Zaire)




Fig. 3B

MARBURG




Fig. 3C




Fig. 4A

PMO

Sequence

1) PMO 0-1-63-542 (EBOLA-VP35-16)	5' - GTC ATC TTG TTA GAC C - 3'
2) PMO 0-1-63-540 (EBOLA-VP35-19)	5' - GTC ATC TTG TTA GAC CAG C - 3'
3) PMO 0-1-63-413 (3136-3115(+))	5' - GTT GTC ATC TTG TTA GAC CAG C - 3'
4) PMO 0-1-63-310 (3136-3115(+)-P003)	5' - GTT GTC ATC TTG TTA GAC CAG C - 3'
5) PMO 0-1-63-565 (EBV VP35 5' Term.)	5' - GAT GAA GGT TTT AAT CTT CAT C - 3'
6) PMO 0-1-63-539 (EBOLA-VP35')	5' - CCT GCC CTT TGT TCT AGT TG - 3'

Fig. 4B




Fig. 5




Fig. 6A




Fig. 6B




Fig. 6C




Fig. 7




Fig. 8




Fig. 9A




Fig. 9B




Fig. 10

10/16




Fig. 11A




Fig. 11B




Fig. 11C




Fig. 11D




Fig. 11E




Fig. 11F




Fig. 11G

12/16




Fig. 12




Fig. 13




Fig. 14A




Fig. 14B




Fig. 14C




Fig. 15A




Fig. 15B




Fig. 15C





Fig. 15D

16/16

**Fig. 16**

SEQUENCE LISTING

<110> AVI BioPharma, Inc.
 Stein, David A.
 Iversen, Patrick L.
 Sina, Bavari

<120> Antisense Antiviral Compounds and Methods for Treating a
 Filovirus Infection

<130> 504508072W00

<140> Not Yet Assigned
 <141> Filed Herewith

<150> US 60/624,277
 <151> 2004-11-01

<150> US 60/671,694
 <151> 2005-04-14

<150> Not Yet Assigned
 <151> 2005-11-01

<160> 66

<170> PatentIn version 3.3

<210> 1
 <211> 125
 <212> RNA
 <213> Zaire ebolavirus

<400> 1
 aaugaugaag auuaaaaccu ucaucauccu uacgucaauu gaauucucua gcacucgaag 60
 cuuaaugucu ucaauguaaa agaaaagcug gucuaacaag augacaacua gaacaaaggg 120
 caggg 125

<210> 2
 <211> 125
 <212> RNA
 <213> Zaire ebolavirus

<400> 2
 cguuccaaca aucgagcgcga agguuucaag guugaacuga gagugucuag acaacaaaau 60
 auugauacuc cagacaccaa gcaagaccug agaaaaaacc auggcuaaag cuacgggacg 120
 auaca 125

<210> 3
 <211> 125
 <212> RNA
 <213> Zaire ebolavirus

<400> 3
 agaucugcga accgguagag uuuaguugca accuaacaca cauaaagcau uggucaaaaa 60

gucaauagaa auuuaaacag ugaguggaga caacuuuuuaa auggaagcuu cauauagagag 120
aggac 125

<210> 4
<211> 125
<212> RNA
<213> Zaire ebolavirus

<400> 4
aaaccaaag ugauaagau uaagaaaac cuaccucggc ugaga gagug uuuuuucauu 60
aaccuucac uuguaaacgu ugagcaaaa uguuuuuuuu augag ggcggg uuauauugcc 120
uacug 125

<210> 5
<211> 124
<212> RNA
<213> Zaire ebolavirus

<400> 5
guagauuaag aaaaaagccu gaggaagauu aagaaaaacu gcuua uuggg ucuuuccgug 60
uuuuagauga agcaguugaa auucuuccuc uugauuuua auggc uacac aacauaccca 120
auac 124

<210> 6
<211> 125
<212> RNA
<213> Zaire ebolavirus

<400> 6
ugaacacuua ggggauugaa gauucaacaa ccuuaaagcu ugaggguaaaa cauuggaaau 60
aguuuuuuaga caaaauugcuc ggaaucacaa aaauccgagu auggauucuc guccucagaa 120
aaucu 125

<210> 7
<211> 30
<212> RNA
<213> Zaire ebolavirus

<400> 7
uaaaaauucu ucuuucuuuu uguguguccg 30

<210> 8
<211> 125
<212> RNA
<213> Lake victoria marburgvirus

<400> 8
cuaaaaaucg aagaauuuu aagguuuucu uuauuuuca gaaaagguuu uuuaucucu 60

ucuuucuuuu ugcaaacaau uugaaaauu aauuuucaca augugggacu caucauauau 120
 gcaac 125

<210> 9
 <211> 125
 <212> RNA
 <213> Lake victoria marburgvirus

<400> 9
 uucaucaaa caccccaau uucaaucau acacauaau accauuuuag uagcguuacc 60
 uucauaca aucuagguga uugugaaaag acuuccaaac auggcagaau uaucaacgcg 120
 uuaca 125

<210> 10
 <211> 124
 <212> RNA
 <213> Lake victoria marburgvirus

<400> 10
 gaagaacau aaguguucu uguuagaau auucaucca guuguuuuga guauacucgc 60
 uucauacaa cuucccuca uauuugauc aagauuuuaa augcaacaac cccguggaag 120
 gagu 124

<210> 11
 <211> 125
 <212> RNA
 <213> Lake victoria marburgvirus

<400> 11
 ucccaucuc agcuuguuga auuaauuguu acuaaaguca uucuuuuuaa aauuaauca 60
 cacaagguag uuuggguua uaucuagaac aaauuuuau auggccagu ccagcaaua 120
 caaca 125

<210> 12
 <211> 125
 <212> RNA
 <213> Lake victoria marburgvirus

<400> 12
 ucauucucu cgauacacgu uauaucuuu gcaaaguau gaaaauagc uugucauguu 60
 agacgccagu uauccaucu aagugaauc uuucucaau augcagcau caacucaua 120
 uccug 125

<210> 13
 <211> 125
 <212> RNA
 <213> Lake victoria marburgvirus

<400> 13
cacacaaaa caagagauga ugauuuugug uauc auauaa auaaagaaga auauuaacau 60
ugacauugag acuugucagu cuguuaauau ucuugaaaag auggauuuac auagcuuguu 120
agagu 125

<210> 14
<211> 30
<212> RNA
<213> Lake victoria marburgvirus

<400> 14
caaaaucauc aucucuuguu uuuguguguc 30

<210> 15
<211> 22
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 15
cggacacaca aaaagaaaga ag 22

<210> 16
<211> 22
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 16
gtagccattt aatatcaaga gg 22

<210> 17
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 17
tgggtatgtt gtgtagccat 20

<210> 18
<211> 22
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 18

caagaggaag aatttcaact gc 22

<210> 19
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 19
gtattgggta tgttgtag c 21

<210> 20
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 20
cgtctgggta ttggatatgt t 21

<210> 21
<211> 22
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 21
gttgatcatct tgtagacca gc 22

<210> 22
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 22
cctgcccttt gttctagttg 20

<210> 23
<211> 22
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 23
gatgaaggtt ttaatcttca tc 22

<210> 24
 <211> 18
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Synthetic oligomer

 <400> 24
 gtcacatcttgt agaccagc 18

 <210> 25
 <211> 16
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Synthetic oligomer

 <400> 25
 gtcacatcttgt tagacc 16

 <210> 26
 <211> 22
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Synthetic oligomer

 <400> 26
 cctgccccttt gttctagttg tc 22

 <210> 27
 <211> 20
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Synthetic oligomer

 <400> 27
 ggacgagaat ccatactcgg 20

 <210> 28
 <211> 23
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Synthetic oligomer

 <400> 28
 cagatcttct gaggacgaga atc 23

 <210> 29

<211> 20
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Synthetic oligomer

 <400> 29
 catccagatt ttctgaggac 20

 <210> 30
 <211> 21
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Synthetic oligomer

 <400> 30
 ctcggcgcca tccagatddd c 21

 <210> 31
 <211> 22
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Synthetic oligomer

 <400> 31
 cataactcgga atdddgtgat tc 22

 <210> 32
 <211> 18
 <212> DNA
 <213> Artificial sequence

 <220>

 <223> Synthetic oligomer

 <400> 32
 ggcaatataa cccgcctc 18

 <210> 33
 <211> 19
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Synthetic oligomer

 <400> 33
 ccatttaaaa gttgtctcc 19

 <210> 34
 <211> 19

<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 34
gccatggttt tttctcagg 19

<210> 35
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 35
ctcaggtcctt gcttgggtgc 20

<210> 36
<211> 22
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 36
tgtatcgtcc cgtagcttta gc 22

<210> 37
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 37
gattgtatcg tcccgtagc 19

<210> 38
<211> 22
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 38
ggcgatatta gattgtatcg tc 22

<210> 39
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 39
ttcaaccttg aaaccttgcg 20

<210> 40
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 40
gccatggttt tttctcagg 19

<210> 41
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 41
ttcaaccttg aaaccttgcg 20

<210> 42
<211> 22
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 42
gatgaaggtt ttaatcttca tc 22

<210> 43
<211> 18
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 43
tttttcttaa tcttcatc 18

<210> 44
<211> 21
<212> DNA
<213> Artificial sequence

<220>
 <223> Synthetic oligomer

<400> 44
 gacacacaaa aacaagagat g 21

<210> 45
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Synthetic oligomer

<400> 45
 gctgcatatt gaagaaagg 19

<210> 46
 <211> 22
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Synthetic oligomer

<400> 46
 catcaggata ttgagttgga tg 22

<210> 47
 <211> 21
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Synthetic oligomer

<400> 47
 gtcccacatt gtgaaaatta t 21

<210> 48
 <211> 22
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Synthetic oligomer

<400> 48
 ottggtgcat atatgatgag tc 22

<210> 49
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Synthetic oligomer

<400> 49
gtaaattccat cttttcaag 19

<210> 50
<211> 24

<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 50
caagctatgt aaatccatct tttc 24

<210> 51
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 51
cctaacaagc tatgtaaadc 20

<210> 52
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 52
taacagactg acaagtctca a 21

<210> 53
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 53
caatgttaat attcttcttt a 21

<210> 54
<211> 22
<212> DNA

<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 54
atattcttct ttatttatat gt 22

<210> 55
<211> 22
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 55
gttgcatttt aaatcttgaa tc 22

<210> 56
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 56
cctttaatat tcttcgattt 20

<210> 57
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 57
gttgtaacgc gttgataatt ctg 23

<210> 58
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 58
caagtctcaa tgtcaatggt 20

<210> 59
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligomer

<400> 59

agtctcgact tgctacctca

20

<210> 60
 <211> 22
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Synthetic oligomer

<400> 60
 tgtgcttact gttatactac tc

22

<210> 61
 <211> 12
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic arginine-rich peptide

<400> 61

Arg Arg Arg Arg Arg Arg Arg Arg Arg Phe Phe Cys
 1 5 10

<210> 62
 <211> 14
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic arginine-rich peptide

<220>
 <221> VARIANT
 <222> (2)..(13)
 <223> Xaa=6-aminohexanoic acid

<220>
 <221> VARIANT
 <222> (14)..(14)
 <223> Xaa=beta-alanine

<400> 62

Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Xaa Xaa
 1 5 10

<210> 63
 <211> 17
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic arginine-rich peptide

13

<220>
 <221> VARIANT
 <222> (2)..(16)
 <223> Xaa=6-aminohexanoic acid

<220>
 <221> VARIANT
 <222> (17)..(17)
 <223> Xaa=beta-alanine

<400> 63

Arg Xaa Arg Xaa Arg Xaa Arg Xaa Arg Xaa Arg Xaa Arg Xaa Arg Xaa
 1 5 10 15

Xaa

<210> 64
 <211> 9
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic arginine-rich peptide

<220>
 <221> VARIANT
 <222> (2)..(8)
 <223> Xaa=6-aminohexanoic acid

<220>
 <221> VARIANT
 <222> (9)..(9)
 <223> Xaa=beta-alanine

<400> 64

Arg Xaa Arg Xaa Arg Xaa Arg Xaa Xaa
 1 5

<210> 65
 <211> 8
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic arginine-rich peptide

<220>
 <221> VARIANT
 <222> (2)..(7)
 <223> Xaa=6-aminohexanoic acid

<220>

<221> VARIANT
<222> (8)..(8)
<223> Xaa=beta-alanine

<400> 65

Arg Xaa Arg Arg Xaa Arg Xaa Xaa
1 5

<210> 66
<211> 11
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic arginine-rich peptide

<220>
<221> VARIANT
<222> (2)..(10)
<223> Xaa=6-aminohexanoic acid

<220>
<221> VARIANT
<222> (11)..(11)
<223> Xaa=beta-alanine

<400> 66

Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Xaa Xaa
1 5 10